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The number of people living with HIV (PLWH) ≥65 years old is increasing in the United States 
(US) as PLWH live longer. In 2015, there were nearly 1 million people living with diagnosed HIV 
in the US and under 10% were age ≥65. By 2035, the proportion of PLWH in this age group is 
projected to be 27%. Like the general population of elderly individuals, as they age, PLWH face 
age-related comorbidities, many of which require routine medical care and daily medications, in 
addition to daily antiretroviral therapy (ART) for treatment of HIV. Previous research has found 
that PLWH develop these conditions at higher rates and earlier ages than HIV-negative 
individuals. Therefore, elderly PLWH are particularly vulnerable to the challenges associated 
with multimorbidity and polypharmacy, including remaining adherent to their medications. 
However, in the context of PLWH, “older” has typically been defined as >50 years old, with few 
studies analyzing PLWH age ≥65, a relevant population given Medicare insurance eligibility in 
the US. Additionally, there is a dearth of literature focusing on older HIV-positive women and 
comorbidities. Gaining a better understanding of the non-HIV-related comorbid disease and 
non-ART comedication burden among PLWH age ≥65 is important because these comorbidities 
often require care coordination among multiple providers and because comorbidities may 
negatively impact adherence to ART. 
With a focus on PLWH aged ≥65 living in the US, the objectives of this dissertation were: (1) to 
compare the non-HIV disease and non-ART medication burden among PLWH and HIV-negative 
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individuals; (2) to describe patterns of non-HIV condition co-occurrence among PLWH and HIV-
negative individuals; and (3) to examine the impact of comorbid disease and comedication 
burden on ART adherence among PLWH. 
Using data from 2010 to 2015 in the IBM Watson Health MarketScan® Medicare Supplemental 
insurance database, I selected PLWH and HIV-negative individuals ≥65 years old based on 
diagnoses on medical claims and pharmacy claims for ART. Outcomes included common 
diagnoses and medication classes, prevalence and number of non-HIV conditions, daily non-
ART medications, and ART medication adherence (using proportion of days covered (PDC) 
over a 1-year period, all based on medical and pharmacy claims. To address the first 
dissertation objective, I examined age-standardized prevalence rates for non-HIV conditions 
and prevalence ratios (PRs) and fit sex-stratified multivariable generalized linear models for the 
number of non-HIV conditions and number of daily non-ART medications. For the second 
dissertation objective, I used latent class analysis to identify classes of individuals based on the 
presence of non-HIV comorbid conditions. Separate latent class models were fit to cohorts of 
PLWH, HIV-negative individuals, and HIV-negative individuals matched to the PLWH cohort on 
demographic characteristics. For the third dissertation objective, I modeled the odds of being 
adherent to ART (defined as PDC ≥80%) using separate adjusted logistic regression models for 
PLWH treated with ART with the number of comorbid conditions, the number of comedications, 
and comorbidity classes as the exposures of interest. 
Dissertation Objective 1: I assessed non-HIV conditions and daily non-ART medications 
among 2,359 elderly PLWH and 2,010,513 elderly HIV-negative individuals. PLWH were 
younger (mean age 71 vs. 76 years) and a larger proportion were men (81% vs. 45%). The 
most common diagnoses among both HIV-positive and HIV-negative cohorts were hypertension 
and dyslipidemia. Most non-HIV conditions were more prevalent among PLWH. The largest 
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absolute difference was in anemia (29.6 cases per 100 people vs.11.7) and the largest relative 
difference was in hepatitis C (PR=22.0). The unadjusted mean number of non-HIV conditions 
and daily non-ART medications were higher for PLWH (4.61 conditions and 3.79 medications) 
than HIV-negative individuals (3.94 conditions and 3.41 medications), respectively. In 
generalized linear models with log link and negative binomial distribution where the outcome 
was the number of non-HIV conditions, PLWH had significantly more non-HIV conditions than 
HIV-negative individuals (ratios: men=1.272, [95% CI 1.233-1.312]; women=1.326 [1.245-
1.413]). Among those with >0 daily non-ART medications, men with HIV had significantly more 
non-ART medications than HIV-negative men (ratio=1.178 [1.133-1.226]) in a generalized linear 
model with log link and gamma distribution where the outcome was number of non-ART 
medications. Dissertation Objective 2: When conditions with prevalence ≥15% among PLWH 
were included in latent class models, a 3-class solution was identified for cohorts of PLWH, all 
HIV-negative individuals, and matched HIV-negative individuals: a sickest class with high 
probabilities of multiple non-HIV conditions, a class characterized by hypertension and 
dyslipidemia, and a healthiest class with low probabilities of non-HIV conditions. Nearly 20% of 
the PLWH were assigned to the sickest class compared to 10.5% of the matched HIV-negative 
cohort, with PLWH having higher probabilities of specific non-HIV diagnoses, including kidney 
disease and anemia. Dissertation Objective 3: Lastly, when analyzing the odds of being 
adherent to ART among 1,644 elderly PLWH with logistic regression models, I found that odds 
of non-adherence were significantly higher among PLWH with 5-6 comorbidities compared to 
PLWH with 0-2 comorbidities (adjusted odds ratio [AOR]=1.420 [95% CI 1.035-1.947]). After 
controlling for the number of comedications, PLWH with 5-6 comorbid conditions (AOR=1.589 
[95% CI 1.131-2.232]) and PLWH with ≥7 conditions (AOR=1.528 [95% CI 1.049-2.225]) were 
50%-60% more likely to be non-adherent than PLWH with 0-2 conditions. Additionally, PLWH 
belonging to the hypertension/dyslipidemia/diabetes comorbidity class were more likely to be 
non-adherent than PLWH in the healthiest class (AOR=1.319 [95% CI 1.047-1.661]). 
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In conclusion, I found that the disease burden associated with aging is substantially higher 
among PLWH age ≥65 than similarly aged HIV-negative individuals, and that there was a trend 
of decreasing ART adherence with increasing comorbid disease burden among PLWH. Due to 
the greater comorbid disease burden, elderly PLWH in the US require additional services and 
care coordination to effectively manage both HIV and comorbid conditions, particularly those 
who have a large number of comorbid conditions. Because multimorbidity may have a negative 
impact of ART adherence, there is a need for interventions focused on primary and secondary 
prevention of comorbidities and ART adherence among elderly PLWH. Future analyses may 
include additional analyses with larger samples of older HIV-positive women, assessments of 
comorbidities and ART medication adherence using other data sources where HIV-specific 
variables like duration of infection, CD4 and viral load are available, an evaluation of PLWH’s 
adherence to comedications, such as antidiabetes medications and antihypertensives, and an 
estimation of the cost impact of comorbid conditions among older PLWH in the US.
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Chapter 1: Introduction 
Human immunodeficiency virus (HIV) is a virus that attacks the CD4 cells in humans, leaving 
the infected individual at an increased risk for infection and infection-related cancers.1 As of 
2009, there were an estimated 1,148,200 people living with HIV (PLWH) over 12 years old in 
the United States (US), comprising 0.5% of the population.2,3 Approximately 47,500 new 
infections occur each year4 with the majority of new diagnoses (77.8%) in individuals aged 20 to 
50 years old.5 As a result of tolerable and effective highly active antiretroviral therapy ART, life 
expectancy for PLWH has increased dramatically. 6 Therefore, the prevalence of HIV among 
older populations in the US is increasing, making elderly PLWH an important group. The 
proportion of PLWH in the US ≥65 years old is projected to increase from 5.4% in 2015 to 
26.9% in 2035.7 
Older PLWH may face health challenges related to age in addition to challenges related to their 
HIV infection. Among older individuals in the US, there is a high prevalence of multimorbidity 
and polypharmacy. In the US, it has been estimated that 86% of people ≥65 years old have at 
least one chronic health condition8 and 64% used ≥3 drugs in the past month.9 Patients’ 
multimorbidity and polypharmacy can pose challenges for healthcare providers, who must 
attempt to co-manage multiple conditions in a single patient while avoiding possible drug-drug 
interactions. For PLWH, multimorbidity and polypharmacy further complicates care and may 
impact their adherence to ART, which is required to experience the clinical and immunological 
benefits of the therapy, and may affect adherence to other medications for chronic conditions as 
well. 
Research has shown that PLWH tend to have more non-HIV health conditions than similarly 
aged HIV-negative individuals, and that these differences become more pronounced after ages 
40-50 years.10-12 Potential mechanisms for this finding include the long-term effects of HIV 
2 
 
infection itself, side effects of ART, or prevalence of risk factors for comorbidities.13,14 
Additionally, older PLWH also use more medications in total and more non-antiretroviral 
medications than older HIV-negative individuals15 and the number of non-antiretroviral 
medications increases with age.16  Therefore, older PLWH and their healthcare providers face 
the challenges of managing HIV infection, including complex antiretroviral medication regimens, 
as well as common age-related conditions, many of which also require daily pharmacotherapy. 
While the number of health conditions directly increases clinical complexity, the number of 
health conditions also affects clinical complexity indirectly, through the interrelatedness of 
conditions and patterns of comorbidity.17 
Comorbidities and concomitant medications may affect ART adherence in older PLWH. The 
negative impact of psychiatric comorbidities like depression, which affects more than half of 
PLWH aged 50 or older,18 on adherence is well-studied.19 However, less research into the 
impact of other comorbidities exists in the literature. Of particular interest are comorbidities 
which require daily medications, as a larger number of comedications may be associated with 
lower ART adherence in a different strength or pattern than the number of comorbidities.20 
Results from qualitative research indicate that PLWH with comorbid conditions may prioritize 
one medication over another.21 Participants with both HIV and diabetes reported that they were 
more adherent to their ART than diabetes medications because they felt that ART was more 
necessary.21   
The results of this dissertation build upon the existing literature in several ways. First, to date, 
little research has focused on PLWH aged 65 and older. Most analyses of “older” PLWH have 
defined “older” as ≥50 years old. This may be due to lack of a sufficient number of individuals 
aged ≥65 in earlier analyses. In the US, however, 65 is a policy-relevant age cut-point because 
it ties to eligibility for Medicare insurance and is commonly used as the definition of elderly in 
non-HIV-specific analyses. Second, I stratify several analyses by sex, and therefore, report 
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results for older women with HIV, a group that has largely been missing from the literature. A 
large portion of previously published US-based analyses in this topic area were conducted with 
data from the Veterans Administration healthcare system. While these data are a rich source of 
information, over 90% of the sample are men, and they may not be representative of all men 
with HIV in terms of socioeconomic status and risk behaviors. Therefore, comorbidities among 
older HIV-positive women and non-veteran HIV-positive males are not well described. 
Descriptions of the patterns of disease co-occurrence for PLWH age 65 and older are also 
lacking in the literature. Lastly, I examined a wide array of non-HIV health conditions, including 
both physical and mental health conditions. While conditions like depression have shown strong 
associations with lower ART adherence, less research has been conducted on the impact of 
non-mental health chronic conditions, polypharmacy, and patterns of comorbidities on ART 
adherence. 
In the US, the population of PLWH age ≥65 is growing and will continue to increase as PLWH 
age and more effective and tolerable antiretroviral medications are developed. Understanding 
the comorbidities facing PLWH within this age group overall and understanding potential 
differences by sex, as well as their impact on ART adherence, is key to designing appropriate 
interventions to aid in the co-management of HIV and multiple comorbidities. The results of this 
analysis will aid healthcare providers and policy makers in caring for elderly PLWH by providing 
insights into the impact of comorbidities and comedications on ART adherence, potentially 
leading to different focuses of adherence counseling or other interventions to promote or 
enhance optimal medication adherence. 
The specific aims of this dissertation were: 
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Aim 1a. To describe the most common non-HIV health conditions and the most common non-
HIV medications among older (age ≥65) PLWH and older HIV-negative individuals overall and 
by sex. 
Aim 1b. To compare the number of non-HIV health conditions, number of non-HIV medications, 
and the prevalence of several pre-specified health conditions between older PLWH and older 
HIV-negative individuals, accounting for sex and age in multivariable models.  
Hypothesis 1. Older PLWH will have significantly higher prevalence of non-HIV 
conditions and non-HIV medications than older HIV-negative individuals.  
Aim 2. To discern patterns of co-occurrence of non-HIV health conditions among older PLWH 
and older HIV-negative individuals, using analyses to group co-occurring conditions. 
Hypothesis 2. Specific patterns of disease co-occurrence will be different in older PLWH 
than patterns of co-occurrence in older HIV-negative individuals and may be driven by 
factors related to HIV medications, HIV risk factors, and chronic inflammation. 
Aim 3. To evaluate the association between ART adherence and comorbid 
disease/comedication burden among older HIV-positive individuals on ART, using multivariable 
models to control for confounding.  
Hypothesis 3. ART medication adherence will be lower among those with higher number 
of comorbidities, higher number of non-HIV medications, and with certain patterns of 
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Chapter 2: Non-HIV Comorbid Conditions and Polypharmacy among People Living with 
HIV Age 65 or Older Compared with HIV-negative Individuals Age 65 or Older in the 




The number of people living with HIV (PLWH) ≥65 years old is increasing in the US. By 2035, 
the proportion of PLWH in this age group is projected to be 27%. As PLWH live longer, they 
face age-related comorbidities. I compared non-HIV disease and medication burden among 
PLWH (n=2,359) and HIV-negative individuals (n=2,010,513) ≥65 years old using MarketScan® 
Medicare Supplemental health insurance claims from 2009-2015. Outcomes were common 
diagnoses and medication classes, prevalence of non-HIV conditions, number of non-HIV 
conditions, and daily non-ART medications over a 1-year period. I examined age-standardized 
prevalence rates and ratios (PRs) and fit multivariable generalized linear models, stratified by 
sex. PLWH were younger (mean 71 vs. 76 years) and a larger proportion were men (81% vs. 
45%). The most common diagnoses among both cohorts were hypertension and dyslipidemia. 
Most non-HIV conditions were more prevalent among PLWH. The largest absolute difference 
was in anemia (29.6 cases per 100 people vs.11.7) and the largest relative difference was in 
hepatitis C (PR=22.0). Unadjusted mean number of non-HIV conditions and daily non-ART 
medications were higher for PLWH (4.61 conditions and 3.79 medications) than HIV-negative 
individuals (3.94 and 3.41). In models, PLWH had significantly more non-HIV conditions than 
HIV-negative individuals (ratios: men=1.272, [95% CI 1.233-1.312]; women=1.326 [1.245-
1.413]). Among those with >0 daily non-ART medications, men with HIV had significantly more 
non-ART medications than HIV-negative men (ratio=1.178 [1.133-1.226]). The disease burden 
associated with aging is substantially higher among PLWH, who may require additional services 




In the US, there is a high prevalence of multimorbidity and polypharmacy, the presence of 
multiple comorbid conditions and the use of multiple medications, especially among older 
persons. An estimated 26.5% of people 18-44 years old have ≥1 chronic condition compared to 
85.8% of people ≥65 years old.1 Among individuals aged 20-59, 17.3% used more than 3 
medications in the past month while among those aged ≥60 years, an estimated 27.3% used 3-
4 medications in the past month and 36.7% used ≥5.2 Patients’ multimorbidity and 
polypharmacy can pose challenges for healthcare providers, who must attempt to co-manage 
multiple conditions in a single patient while avoiding possible drug-drug interactions.  
The introduction of effective and tolerable combination antiretroviral therapy (ART) has 
dramatically extended the lifespans of people living with HIV (PLWH).3 Older PLWH and their 
healthcare providers must manage HIV infection along with multiple other common age-related 
conditions. Evidence indicates that PLWH develop these conditions at higher rates and earlier 
ages than HIV-negative individuals, making elderly PLWH particularly vulnerable to the 
challenges associated with multimorbidity and polypharmacy.4-7 Potential mechanisms for this 
finding include the long-term effects of HIV infection itself, side effects of ART, or prevalence of 
risk factors for comorbidities.8,9 
To date, much of the research on older PLWH has defined “older” as >50 years old.5,7,10-12 Little 
research has focused on PLWH who would traditionally be considered elderly in the US – those 
aged 65 and older insured through Medicare – who may have different comorbidity profiles than 
those 50+ years old.13 The number of PLWH who are ≥65 years old is increasing in the US. By 
2035, the proportion of PLWH in this age group is projected to be nearly 27%.14 Additionally, 
most research has been limited to HIV-positive men with analyses of HIV-positive women have 
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focusing on specific conditions, such as heart disease and cognitive impairment,15-19 rather than 
the overall burden.  
My objective was to compare the non-HIV disease and non-ART medication burden among 
elderly PLWH to that of elderly HIV-negative individuals, overall and by sex. I evaluated the 
most common diagnoses and medication classes and the prevalence of non-HIV conditions 
within the two groups, as well as the number of non-HIV conditions and the number of daily non-
ART medications.  
METHODS 
Data Source 
This observational, cross-sectional analysis was conducted using the IBM Watson Health 
MarketScan® Medicare Supplemental and Coordination of Benefits Database, a proprietary 
administrative healthcare claims database, comprising healthcare claims for over 9 million 
covered lives from 1995 to 2015. Enrollees are insured through Medicare supplemental 
insurance plans paid for by employers. The data include enrollee demographic and enrollment 
information, inpatient and outpatient medical claims, and outpatient pharmacy claims. Patients 
enter the database when their enrollment begins and exit the database when they disenroll or 
die. 
The CUNY SPH Institutional Review Board granted this study IRB exemption. The MarketScan 
database satisfies the conditions set forth in Sections 164.514 (a)-(b)1ii of the Health Insurance 
Portability and Accountability Act of 1996 privacy rule regarding the determination and 




PLWH ≥65 years old and HIV-negative individuals ≥65 years old were selected. The group of 
PLWH included individuals with (a) ≥2 non-diagnostic claims with an ICD-9-CM diagnosis of HIV 
(042, 795.71, V08, 079.53) in any position (primary or secondary) or (b) 1 non-diagnostic claim 
with an HIV diagnosis and ≥1 claim for ART between January 1, 2010 and September 30, 2015. 
A non-diagnostic claim is one that has a procedure code for a procedure other than a laboratory 
or radiology test, known as diagnostic claims. As all claims require a diagnosis, the suspected 
diagnosis may appear on a diagnostic claim, regardless of the results of the test. Therefore, 
diagnoses appearing on diagnostic claims are typically ignored when defining a patient 
population. The comparator group comprised individuals with no claims with HIV diagnosis and 
no claims for ART from January 1, 2009 to September 30, 2015 (referred to as “HIV-negative 
individuals”). 
The service date on a patient’s most recent claim with an HIV diagnosis was referred to as the 
index date. The most recent date with an HIV diagnosis was chosen as the index date in order 
to evaluate non-HIV health conditions and non-ART medication use at an individual’s oldest age 
in the database to maximize the sample size among the upper distribution of age (e.g., 
someone who is 65 years old in 2010 but has data that with an HIV ICD-9-CM diagnosis code 
through 2014 would be analyzed as a 70-year old using the most recent year of data). A 
pseudo-index date for HIV-negative individuals was randomly assigned based on the 
distribution of calendar year for index dates among selected PLWH. The index date for HIV-
negative individuals was not tied to any diagnosis or healthcare encounter.  
Individuals with an HIV diagnosis on only one non-diagnostic claim and no ART medication 
claims during the patient selection period were excluded from the analysis, because it is unclear 
whether or not these individuals had HIV. 
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PLWH and HIV-negative individuals were required to have 12 months of continuous enrollment 
in the Medicare Supplemental database prior to their index date to evaluate the study outcomes 
(evaluation period). This requirement was made to ensure that if the enrollee saw a healthcare 
provider or filled a prescription which generated a healthcare claim, the diagnosis and 
medications would appear in the database. Patients were required to be ≥65 years old at the 
start of the evaluation period.  
Exposure 
The primary exposure of interest was HIV status. 
Outcomes 
The outcomes were: (a) the most common non-HIV 3-digit ICD-9-CM diagnoses codes 
appearing in the two groups, (b) the most common non-ART therapeutic medication classes for 
pharmacy claims in the two groups, (c) prevalence of non-HIV conditions in the two groups, (d) 
the number of non-HIV health conditions diagnosed in individuals, and (e) the number of daily 
non-ART medications by individuals. All outcomes were based on healthcare claims with 
service dates in the 12 months prior to and including the index date. 
ICD-9-CM diagnosis codes range from 3 to 5 digits in length and are organized in a hierarchical 
structure. To evaluate the most non-HIV health conditions present, the diagnoses codes on 
each non-diagnostic inpatient or outpatient claim were rolled up to the 3-digit level to combine 
similar conditions. On outpatient pharmacy claims, therapeutic class was based on RedbookTM, 
a database containing drug product information. All unique 3-digit ICD-9-CM diagnosis codes 
present/unique therapeutic classes filled among the PLWH group were identified and the 
number and proportion of individuals with each diagnosis/therapeutic class was captured. This 
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process was repeated for the men with HIV, women with HIV, the overall HIV-negative group, 
HIV-negative men and HIV-negative women. 
The prevalence of the following conditions were evaluated: ischemic heart disease (including 
myocardial infarction, angina, and atherosclerosis), congestive heart failure, cardiac 
dysrhythmia, hypertension, dyslipidemia, non-rheumatic heart valve disorders, peripheral 
vascular disease, dementia, cerebrovascular disease, rheumatologic disease, osteoarthritis, 
osteoporosis, peptic ulcer disease/esophageal reflux, liver disease, hepatitis C, diabetes, 
hemiplegia/paraplegia, kidney disease, non-AIDS defining cancer (cancers other than Kaposi’s 
sarcoma, cervical cancer, and non-Hodgkin’s lymphoma), benign prostate hyperplasia, anemia, 
unspecified acquired hypothyroidism, glaucoma, cataract, retinal disorders (including non-
diabetic retinopathy, and retinal or macular degeneration), anxiety, depression, schizophrenia, 
bipolar disorder, substance abuse, and tobacco use disorder. The list was based on conditions 
included in the Deyo Charlson Comorbidity Index,20 which is a claims-based comorbidity score 
commonly used in the claims-based analyses consisting of 15 health conditions in addition to 
HIV, the most common diagnoses in both PLWH and HIV-negative individuals in this dataset, 
and conditions including in other analyses of comorbidities.4,5,7,21-23 I also captured AIDS-
defining cancers (Kaposi’s sarcoma, cervical cancer, and non-Hodgkin’s lymphoma). An 
individual was considered to have a condition if he or she had ≥1 non-diagnostic claim with the 
relevant diagnosis or procedure code during the 12-month evaluation period. For each HIV-
positive and HIV-negative individual, the number of aforementioned non-HIV conditions of 
interest present was calculated (minimum of 0 and maximum of 32) as was the number of daily 
non-ART medications. AIDS-defining cancer did not contribute to the number of non-HIV 
conditions. To calculate the number of daily medications, the days’ supplies of all outpatient 
pharmacy claims during the 12-month evaluation period were summed and the sum was divided 
by 366 days, in a method similar to the calculation for medication possession ratio.24 
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In a sensitivity analysis, the following conditions were not included when summing the number 
of non-HIV conditions because of their potential to be adverse events of ART:25 hypertension, 
osteoporosis, ischemic heart disease, dyslipidemia, liver disease, depression, kidney disease 
and anemia. 
Covariates 
The following demographic characteristics were based on enrollment information: age, US 
Census Bureau region,26 and urbanicity based on residence in a Metropolitan Statistical Area.27 
These variables were included as covariates because they may be risk factors for certain health 
conditions or affect risk factors.   
Analyses 
Demographic characteristics were stratified by HIV status and sex and compared using t-tests 
and chi-squared tests. The most common diagnoses and medication therapeutic classes were 
ranked. Among conditions that were present in ≥15% of PLWH or HIV-negative individuals, the 
rank of each condition was compared between PWLH and HIV-negative individuals. The same 
was done for HIV-positive men and women with conditions present in ≥15% of either group. The 
rankings were descriptive in nature and unadjusted; therefore, no statistical comparisons were 
made. Ranks were used as a way of describing the most common conditions/medication 
classes in each group and comparing them between groups, regardless of the prevalence of 
those conditions/medication classes, because the top conditions could be the same between 
the two groups even while the proportion of people with each condition differed. Next, the 
prevalence of each non-HIV condition was compared between PLWH and HIV-negative 
individuals and also between sexes. To account for differences in the age and sex, direct 
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standardization was used to calculate prevalence rates per 100 people with 95% confidence 
intervals. Prevalence ratios (PRs) are also presented.  
Finally, multivariable models were fit to determine the association between HIV status and the 
number of non-HIV conditions and daily non-ART medications. The number of non-HIV 
conditions was modeled using generalized linear models with a log link and negative binomial 
distribution. The number of daily non-ART medications was modeled in a two-stage process 
because of the proportion of individuals with 0 medications. The odds of having 0 non-ART 
medications was modeled using logistic regression models. Among patients who had a non-
ART medication, the number of daily non-ART medications was modeled using generalized 
linear models with log link and gamma distribution. In all models, the primary exposure was HIV 
status and covariates were age group, region, urbanicity. Separate models were fit for men and 
women. P-values less than 0.05 were considered statistically significant. However, given the 
large size of the PLWH cohort in this analysis, the magnitude of the effect estimates should be 
considered in addition to the p-values. 
Analyses were conducted with SAS 9.4 (Cary, NC). 
RESULTS 
Patient Selection and Patient Characteristics 
Overall, 2,359 individuals (1,909 men and 450 women) met my criteria for being HIV-positive 
and 2,010,513 people (895,123 men and 1,115,390 women) met my criteria for the HIV-
negative comparison group (Appendix 1 Figure 1). Mean age was significantly lower for PLWH 
than HIV-negative individuals (71.42 vs. 76.01 years, p<0.001; Table 1). A significantly larger 
proportion of PLWH were men (80.92% vs. 44.52%, p<0.001) and lived in an urban area than 
HIV-negative individuals (93.22% vs. 84.14%, p<0.001). Similar trends were noted when 
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comparing HIV-positive men to HIV-negative men and HIV-positive women to HIV-negative 
women (Appendix 1 Table 1). Among PLWH, men were significantly younger than women 
(p<0.001) and the proportion of men living with HIV and residing in the South was significantly 
higher than women with HIV who more commonly lived in the Northeast or West (p<0.001; 
Table 1). 
Most Common Diagnoses and Medications 
The diagnoses ranked 1st, 2nd, and 3rd among both PLWH and HIV-negative individuals were 
essential hypertension (ICD-9-CM 401; PLWH=47.9% vs. HIV-negative=59.4%), disorders of 
lipid metabolism (ICD-9-CM 272; 35.7% vs. 46.9%), and symptoms involving respiratory system 
and other chest symptoms (ICD-9-CM 786; 31.3% vs. 26.3%; Table 2). Differences in rank were 
noted for diagnoses of symptoms involving the urinary or digestive symptoms (ICD-9-CM 788 
and 787), which were more highly ranked and more common among PLWH (ranked 15 and 16th 
most common among PLWH vs. 27 and 28th among HIV-negative individuals). Other retinal 
disorders (ICD-9-CM 362) and osteoarthritis and allied disorders (ICD-9-CM 715) were ranked 
higher among HIV-negative individuals (ranked 15th and 11th most common among HIV-negative 
individuals vs. 28th and 29th among PLWH). For both PLWH and HIV-negative individuals, 
therapeutic medication classes related to heart conditions were commonly used (ranks 1st, 2nd, 
4th, and 5th most common among PLWH vs. ranks 1st through 4th among HIV-negative 
individuals). Non-HIV antiviral medications, including those used for influenza, viral hepatitis, 
cytomegalovirus, herpes, were more common among PLWH than among HIV-negative 
individuals (ranked 11th most common among PLWH vs. outside of the top 20 conditions for 
HIV-negative individuals). Thyroid medications were ranked higher among HIV-negative 




Diagnoses of other forms of chronic ischemic heart disease (ICD-9-CM 414, such as coronary 
atherosclerosis and aneurysm of heart or coronary vessels), of other dermatoses (ICD-9-CM 
702, such as actinic or seborrheic keratosis), and of symptoms involving the urinary system 
(ICD-9-CM 788) were ranked higher and were more common among men living with HIV 
compared to women living with HIV, whereas special screening for malignant neoplasms (ICD-
9-CM V76), other and unspecified anemias (ICD-9-CM 285), and osteoarthritis and allied 
disorders were ranked higher among women with HIV (Appendix 1 Table 2). Unclassified 
agents (which includes medications for benign prostate hyperplasia) and non-HIV antivirals 
were more highly ranked among men living with HIV than women living with HIV. 
Prevalence of Non-HIV Conditions 
After age-sex standardization, hypertension and dyslipidemia remained the most prevalent non-
HIV conditions for both PLWH and HIV-negative individuals (Figure 1A). However, the rates 
were higher among PLWH than HIV-negative individuals (hypertension=68.4 per 100 [95% CI 
62.6-74.2] vs. 60.9 [60.8-61.0]; dyslipidemia=54.0 per 100 [95% CI 49.1-59.0] vs. 46.9 [46.8-
47.0]). Most conditions examined were more prevalent among PLWH. The largest absolute 
differences were seen in anemia (29.6 per 100 [95% CI 25.4-33.8] vs.11.7 [95% CI 11.6-11.7]) 
and kidney disease (20.5 per 100 [95% CI 17.4-23.7] vs. 8.1 [95% 8.0-8.1]). The largest relative 
differences were found among less prevalent conditions: hepatitis C (PRPLWH vs. HIV-negative =22.0), 
liver disease (PRPLWH vs. HIV-negative=4.4), and schizophrenia (PRPLWH vs. HIV-negative=3.2). AIDS-
defining cancer was also more prevalent among PLWH (PRPLWH vs. HIV-negative=3.8). Among 
PLWH, large differences in age-standardized prevalence rates were noted in the prevalence of 
osteoporosis which was more common among women (PLWH men=3.0 per 100 [95% CI 1.9-
4.2] vs. PLWH women=12.9 [95% CI 8.5-17.2]; PRmen vs. women=0.2) and hemiplegia/paraplegia 
which was more common among men (PLWH men=1.9 [95% CI 0.9-2.8] vs. PLWH women=0.4 
[95% CI 0-0.9]; PRmen vs. women=4.7) (Figure 1B). Comparisons of prevalence rates between HIV-
18 
 
positive men and HIV-negative men and HIV-positive women and HIV-negative women were 
similar to the overall PLWH and HIV-negative comparisons (Appendix 1 Figure 2A and B). 
Multimorbidity and Polypharmacy 
In unadjusted analyses, the average number of non-HIV conditions and average number of daily 
non-ART medications were 4.61 conditions (median=4) and 3.79 medications (median=3.16) for 
PLWH compared to 3.94 conditions (median=4) and 3.41 medications (median=2.95) among 
HIV-negative individuals (Appendix 1 Table 3). While over three-quarters of the PLWH and HIV-
negative cohorts had ≥2 non-HIV conditions and more than one-quarter had ≥5 daily non-ART 
medications, both were more common among PLWH. The number of comorbid conditions was 
similar between HIV-positive men and HIV-positive women; however, HIV-positive men tended 
to use more non-ART medications.  
The number of non-HIV conditions and daily non-ART medications increased with age for both 
PLWH and HIV-negative individuals (Figure 2A and B). Within each age stratum, the number of 
non-HIV conditions was higher for PLWH. The mean and median number of conditions for 
PLWH aged 65-69 was similar to those HIV-negative individuals aged 75-79 (PLWH mean=4.02 
[median=4] vs. HIV-negative =4.21 [4]) whereas PLWH 70-74 years old were similar to HIV-
negative individuals ≥85 years old (PLWH mean=4.69 [median=4] vs. HIV-negative =4.70 [4]). 
Trends were similar when evaluating daily non-ART medications with PLWH 65-69 years old 
resembling HIV-negative individuals 70-74 years old (PLWH mean=3.58 [median=2.92] vs. HIV-
negative =3.62 [3.21]) and PLWH 70-74 years old resembling HIV-negative individuals aged 80-
84 (PLWH mean=3.88 [median=3.18] vs. HIV-negative =3.83 [3.48]). 
In adjusted models, men living with HIV had 27% (ratio=1.272, 95% CI 1.233-1.312) more non-
HIV conditions than HIV-negative men and women living with HIV had 33% (ratio=1.326, 95% 
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CI 1.245-1.413) more non-HIV conditions than HIV-negative women (Table 3). Results were 
similar when excluding conditions which may be side effects of ART. HIV-positive men were 
48% (ratio=0.523, 95% CI 0.427-0.642) less likely to have no non-ART medications than HIV-
negative men and among those with non-ART medications, had 18% more daily non-ART 
medications (ratio=1.178, 95% CI 1.133-1.226) than HIV-negative men. Similar trends were 
found when comparing HIV-positive women and HIV-negative women; however, the effect 
estimates were smaller and were not significant or were marginally significant (p=0.043 in 
adjusted model). Age was found to be a strong positive predictor of both the number of non-HIV 
conditions and daily non-ART medications (Appendix 1 Tables 4A-3C). 
DISCUSSION 
I found that the most common diagnoses and medications used were similar among elderly 
PLWH and HIV-negative individuals in the US. However, many common conditions were more 
prevalent among PLWH. PLWH tended to have a greater non-HIV disease burden and non-ART 
medication burden, each similar to that of HIV-negative individuals between 5 and 10 years 
older. Differences in non-ART medication use were larger when comparing HIV-positive men to 
HIV-negative men, than when comparing HIV-positive and HIV-negative women where the 
differences were only marginally significant. 
Other analyses conducted in resource-rich countries and in younger patient populations have 
also shown that PLWH tend to have more non-HIV health conditions than similarly aged HIV-
negative individuals, and that these differences become more pronounced after ages 40-50 
years.4-6,28,29 PLWH have been found to be at higher risk for cardiovascular disease,15,30-35 
stroke,33,36,37 renal disease,7,30,33,34 malignancies,30,33,38 chronic obstructive pulmonary disorder,39 
bone fractures,7,33,34 and diabetes.7,29,34 Older PLWH also use more medications in total and 
more non-ART medications than older HIV-negative individuals.40-42 Similar to my analysis, a 
20 
 
Spanish study of people 50-64 years old found that HIV-positive men had more concomitant 
meds and more long-term polypharmacy than HIV-negative men.43 HIV-positive women had 
similar numbers of concomitant medications but more long-term polypharmacy than HIV-
negative women.43 Other comparative analyses conducted in the Netherlands and in Italy have 
also reported that PLWH resemble HIV-negative individuals 5 to 10 years older in terms of non-
HIV disease and non-ART medication burden.4,7 Interestingly, small epigenetic studies of DNA 
methylation of PLWH and HIV-negative individuals have reported similar results.44,45  
The proportion of PLWH in the US ≥65 years old is projected to increase from 5.4% in 2015 to 
26.9% in 2035. In 2035, 44% of PLWH in this age group are projected to have ≥3 comorbid 
conditions, driven by hypertension, dyslipidemia, diabetes, and cancer.14 Additionally, 
multimorbidity appears to be increasing among PLWH over time regardless of age.46 Caring for 
these patients will involve managing multiple non-HIV conditions and multiple non-ART 
medications, in addition to HIV and ART.47  
Multimorbidity and polypharmacy among elderly PLWH are of significant clinical concern. 
Comorbidities like chronic kidney disease and cardiovascular disease have been associated 
with increased 5-year mortality48 and a higher number of comorbidities has been associated 
with lower self-reported quality of life in both HIV-positive and HIV-negative individuals.49 In the 
general population, polypharmacy has been associated with short-term mortality, frailty, 
disability, and adverse drug events.50-54 Many medications for comorbid conditions, like 
cardiovascular disease, may interact with certain types of ART55,56 and several studies have 
found that drug-drug interactions are common among PLWH.12,57-59 Both multimorbidity and 
polypharmacy have been associated with lower adherence to ART and other medications.60,61 
Additionally, PLWH with comorbid conditions may prioritize ART over other medications, such 
as diabetes medications, potentially leading to worse outcomes for comorbid conditions.62 
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The potential mechanisms by which HIV infection may result in multimorbidity include chronic 
inflammation and immune compromise by the virus, side effects of ART that negatively 
influence ART adherence or that develop into chronic conditions, or the higher prevalence of 
traditional risk factors for certain chronic conditions among PLWH.8,9 Longer duration of HIV 
infection has been found to drive comorbidity prevalence independent of age.6 Even PLWH with 
successfully controlled HIV have higher mortality rates compared to age-matched HIV-
controls.63 ART is also associated with adverse events, including decreases in bone density, 
dyslipidemia, hepatitis/liver disease, and chronic kidney disease;25 however, an increased 
disease burden was still associated with HIV when these conditions were excluded. Additionally, 
the increased number of comorbidities reported among PLWH may be due to higher prevalence 
of disease risk factors, such as smoking and substance abuse.28,39 Another potential factor is 
low rates of receipt of guideline-recommended care, specifically prescriptions for aspirin and 
statins for cardiovascular disease, among PLWH.64,65 
The strengths of my analysis include examining a large, geographically diverse population of 
PLWH ≥65 years old. Age 65 is the traditional cut-off used to define “older” in general population 
in the US and is linked to eligibility for Medicare insurance. I also stratified my results by sex. 
Many previously published US-based analyses have utilized data from the Veterans 
Administration healthcare system, where >90% of the sample are men. Lastly, I evaluated all 
diagnoses and medications recorded in the individuals’ claims histories over a year-long period 
and included a wide range of non-HIV conditions, including both physical and mental health 
conditions.  
This study also has limitations. First, claims are generated for billing purposes. There may be 
coding errors. Patients may receive a misdiagnosis that is recorded in claims and conditions for 
which they do not seek care will not appear in the database. Healthcare services covered by 
other insurance plans, such as Medicaid, or paid for out-of-pocket would also not appear in the 
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database. HIV status was inferred from claims and misclassification may have occurred if 
patients in the HIV-negative cohort had undiagnosed or untreated HIV. However, the proportion 
of undiagnosed patients is likely very small relative to my total number of HIV-negative 
individuals and therefore, is unlikely to have affected my conclusions. Second, race, 
socioeconomic status, lifestyle behaviors, and HIV-related variables, such as disease duration, 
viral load, and CD4 counts, are not available in claims data. Because of this limitation, I could 
not evaluate potential causal relationships between HIV duration, ART use, or risk factors and 
multimorbidity or polypharmacy. Substance abuse and tobacco use disorder are likely under-
coded 
Third, I assumed that patients took their medications as directed (e.g., a 30-day fill was taken for 
30 days). The calculation of daily medications did not account for the length of time on the 
medication. Medications for short-term conditions, such as antibiotics for infection, contributed 
to the calculation for this analysis, while over-the-counter medications are not included. Fourth, 
the individuals analyzed had Medicare Supplemental and likely have higher socioeconomic 
status and more generous medical and pharmacy benefits than other elderly PLWH, limiting 
generalizability. Despite having more women than other studies, the number of HIV-positive 
women was still small, and more research is needed to evaluate multimorbidity and 
polypharmacy in women. Lastly, PLWH may be in more contact with healthcare providers than 
HIV-negative individuals which may result in more frequent screenings for and earlier diagnosis 
of non-HIV conditions and more prescriptions.  
In conclusion, elderly PLWH experience many of the same non-HIV conditions as elderly HIV-
negative individuals; however, PLWH tend to have more non-HIV conditions and use more 
medications. Understanding the comorbidities facing elderly PLWH is key to the effective co-
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CHAPTER 2 TABLES AND FIGURES 
Chapter 2 Table 1. Demographic characteristics of PLWH and HIV-negative individuals 




PLWH: Men PLWH: Women 
p-value   N=2,359 N=2,010,513 N=1,909 N=450 
 N/Mean %/SD N/Mean %/SD 
 N/Mean %/SD N/Mean %/SD  
           
Age (Mean, SD) 71.42 5.19 76.01 7.56 <0.001 71.26 4.91 72.12 6.20 0.001 
              
 
Age group (N, %)               
65-69 1,084 45.95% 498,688 24.80% <0.001 884 46.31% 200 44.44% <0.001 
70-74 770 32.64% 501,139 24.93%  628 32.90% 142 31.56%  
75-79 301 12.76% 383,888 19.09%  253 13.25% 48 10.67%  
80-84 122 5.17% 306,351 15.24%  92 4.82% 30 6.67%  
85+ 82 3.48% 320,447 15.94%  52 2.72% 30 6.67%  
          
     
Men (N, %) 1,909 80.92% 895,123 44.52% <0.001      
           
Region (N, %)               
Northeast 653 27.68% 460,866 22.92% <0.001 503 26.35% 150 33.33% <0.001 
North Central 350 14.84% 640,903 31.88%  287 15.03% 63 14.00%  
West 720 30.52% 598,610 29.77%  543 28.44% 177 39.33%  
South 615 26.07% 300,761 14.96%  560 29.33% 55 12.22%  
Unknown 21 0.89% 9,373 0.47%  16 0.84% 5 1.11%  
               
Urbanicity (N, %)               
Urban 2,199 93.22% 1,691,591 84.14% <0.001 1,793 93.92% 406 90.22% 0.019 
Rural 143 6.06% 310,512 15.44%  104 5.45% 39 8.67%  
Unknown 17 0.72% 8,410 0.42%  12 0.63% 5 1.11%  
         
      




Chapter 2 Table 2. Rank and prevalence of 3-digit diagnoses and therapeutic classes present in 
≥15% of PLWH or HIV-negative individuals 
 
  PLWH HIV-negative Individuals 
  Rank N % Rank N % 
Most Common 3-Digit ICD-9-CM Diagnosis Codes (N, %)             
401 Essential hypertension 1 1,129 47.9% 1 1,195,074 59.4% 
272 Disorders of lipid metabolism 2 842 35.7% 2 942,840 46.9% 
786 Symptoms involving respiratory system and other  
       chest symptoms 3 738 31.3% 3 529,172 26.3% 
780 General symptoms 4 711 30.1% 5 504,101 25.1% 
250 Diabetes mellitus 5 611 25.9% 6 484,451 24.1% 
366 Cataract 6 523 22.2% 4 505,396 25.1% 
729 Other disorders of soft tissues 7 496 21.0% 10 392,912 19.5% 
414 Other forms of chronic ischemic heart disease 8 493 20.9% 9 393,455 19.6% 
719 Other and unspecified disorder of joint 9 479 20.3% 7 430,153 21.4% 
427 Cardiac dysrhythmias 10 433 18.4% 13 363,473 18.1% 
V04 Need for prophylactic vaccination and inoculation  
       against certain viral diseases 11 432 18.3% 12 377,809 18.8% 
702 Other dermatoses 12 423 17.9% 8 398,251 19.8% 
V58 Other and unspecified aftercare 13 389 16.5% 21 259,277 12.9% 
724 Other and unspecified disorders of back 14 370 15.7% 14 346,474 17.2% 
788 Symptoms involving urinary system 15 366 15.5% 27 224,619 11.2% 
787 Symptoms involving digestive system 16 364 15.4% 28 221,690 11.0% 
362 Other retinal disorders 28 281 11.91% 15 309,609 15.40% 
715 Osteoarthritis and allied disorders 29 279 11.83% 11 386,352 19.22% 
Most Common Medication Therapeutic Classes (N, %)             
Antihyperlipidemic Drugs: Not Elsewhere Classified 1 1,309 55.5% 1 1,055,239 52.5% 
Cardiac: Beta Blockers 2 768 32.6% 2 698,536 34.7% 
Analgesics/Antipyretics: Opiate Agonists 3 745 31.6% 5 494,203 24.6% 
Cardiac: ACE Inhibitors 4 696 29.5% 3 525,286 26.1% 
Cardiac: Calcium Channel Blockers 5 576 24.4% 4 505,870 25.2% 
Psychotherapeutic Agents: Antidepressants 6 575 24.4% 8 404,924 20.1% 
Gastrointestinal Drugs Miscellaneous: Not Elsewhere  
Classified 7 559 23.7% 6 456,400 22.7% 
Unclassified Agents, Not Elsewhere Classified* 8 481 20.4% 17 284,251 14.1% 
Quinolones: Not Elsewhere Classified 9 468 19.8% 13 342,238 17.0% 
Antibiotics: Penicillins 10 437 18.5% 11 352,024 17.5% 
Antivirals: Not Elsewhere Classified* 11 437 18.5% >23 82,416 4.1% 
Anxiolytics, Sedatives, and Hypnotics: Benzodiazepines 12 413 17.5% 19 253,656 12.6% 
Analgesics/Antipyretics: Non-steroid/Anti-inflammatory  13 408 17.3% 12 347,236 17.3% 
Adrenals & Combinations: Not Elsewhere Classified* 14 402 17.0% 9 376,190 18.7% 
Antibiotics: Erythromycin & Macrolide 15 392 16.6% 15 291,700 14.5% 
Cardiac Drugs: Not Elsewhere Classified 16 387 16.4% 7 409,221 20.4% 
Anti-inflammatory Skin/Mucous Membrane Agents &  
Combinations: Miscellaneous 17 369 15.6% 18 269,633 13.4% 
Anti-inflammatory Agents Eye, Ear, Nose, and Throat: Not  
Elsewhere Classified 18 364 15.4% 14 325,192 16.2% 
Thyroid/Antithyroid, Thyroid Hormones 31 223 9.45% 10 371,322 18.47% 
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Abbreviations: HIV, human immunodeficiency virus; ICD-9-CM, International Classification of Diseases, Ninth Edition, Clinical 
Modification; PLWH, people living with HIV. 
*Unclassified agents includes medications for benign prostate hyperplasia. Antivirals includes medications for hepatitis, influenza, 
cytomegalovirus, and herpes. Adrenals includes corticosteroids
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Chapter 2 Figure 1A-B. Standardized prevalence of non-HIV conditions and AIDS-defining cancer per 100 people with 95% 
confidence intervals and prevalence ratios for (A) PLWH versus HIV-negative individuals and (B) HIV-positive men versus HIV-








Abbreviations: HIV, human immunodeficiency virus; PLWH, people living with HIV; PR, prevalence ratio. 
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Chapter 2 Figure 2A-B. Number of non-HIV conditions (A) and number of daily non-ART 
medications per day (B), stratified by HIV status and age 
 
 
Abbreviations: HIV, human immunodeficiency virus; PLWH, people living with HIV; yo, years old. 
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Chapter 2 Table 3. Modeling results for number of non-HIV conditions, no non-ART medications, and number of daily non-ART 
medications among those with non-ART medications comparing PLWH and HIV-negative individuals, stratified by sex 
  Model 1: Crude Model 2: Adjusted* 
  
Men: PLWH vs. HIV-
negative Individuals 
Women: PLWH vs. HIV-
negative Individuals 
Men: PLWH vs. HIV-
negative Individuals 
Women: PLWH vs. HIV-
negative Individuals 
 Ratio (95% CI) 
p-
value Ratio (95% CI) 
p-
value Ratio (95% CI) 
p-
value Ratio (95% CI) 
p-
value 
         
Ratio for number of 
non-HIV conditions†  
1.136 (1.100-1.173) <0.001 1.214 (1.138-1.296) <0.001 1.272 (1.233-1.312) <0.001 1.326 (1.245-1.413) <0.001 
Excluding potential 
ART side effects 
    1.243 (1.199-1.288) <0.001 1.221 (1.134-1.315) <0.001 
         
Ratio for odds of 
having no non-ART 
medications† 
0.579 (0.473-0.710) <0.001 0.856 (0.598-1.227) 0.398 0.523 (0.427-0.642) <0.001 0.840 (0.586-1.203) 0.341 
         






1.089 (1.046-1.133) <0.001 1.015 (0.936-1.100) 0.726 1.178 (1.133-1.226) <0.001 1.086 (1.003-1.176) 0.043 
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; PLWH, people living with HIV. 
*Adjusted for age group, region, and urbanicity. 
†Ns for models of number of non-HIV conditions and odds of no non-ART medications were: men with HIV=1,909; HIV-negative men=895,123; women with 
HIV=450; and HIV-negative women=1,115,390. 





Chapter 3: Patterns of Non-HIV Conditions among People Age 65 and Older Comparing 





Elderly people living with human immunodeficiency virus (PLWH) are living longer and 
developing multiple chronic conditions. Understanding multimorbidity among these patients is 
important because they require care coordination between multiple providers and multiple 
comedications in addition to antiretroviral therapy. Using latent class analysis, I described 
classes of individuals based on non-HIV conditions among 2,359 elderly PLWH and 2,010,513 
elderly HIV-negative individuals present in the IBM Watson Health MarketScan® Medicare 
Supplemental insurance claims database. The presence of non-HIV conditions was identified 
based on diagnoses on medical claims. Separate latent class models using non-HIV conditions 
present in ≥15% of PLWH were fit to cohorts of PLWH, HIV-negative individuals, and HIV-
negative individuals matched to the PLWH cohort on demographic characteristics. A 3-class 
solution was identified for each of the three cohorts: a sickest class with multiple comorbidities, 
a class characterized by hypertension and dyslipidemia, and a healthiest class. Nearly 20% of 
the PLWH were assigned to the sickest class compared to 10.5% of the matched HIV-negative 
cohort (p<0.001), with PLWH having higher probabilities having specific non-HIV diagnoses, 
including kidney disease and anemia. An understanding of the patterns of comorbid disease 




With the introduction of effective and tolerable combination antiretroviral therapy (ART) with 
long-term tolerability, people with human immunodeficiency virus (HIV) are living longer1 and, 
like the broader population of older individuals, elderly people living with HIV (PLWH) often have 
more than one non-HIV health condition.2-5 By 2035, the proportion of PLWH age ≥65 in the 
United States is estimated to be 26.9%, an increase from 5.4% in 2015, and 44% are projected 
to have ≥3 comorbid conditions.6 Effectively caring for PLWH with multimorbidity is complex, 
requiring more than simply treating each condition individually.7,8 It requires coordination among 
multiple healthcare providers and multiple medications for comorbidities in addition to ART.9  
Several investigations have reported that specific health conditions are more prevalent in PLWH 
and that PLWH generally have a higher number of non-HIV conditions than HIV-negative 
individuals.3-5,10-22 Potential mechanisms for these findings include the long-term effects of HIV 
infection itself, side effects of ART, higher prevalence of risk factors for comorbidities23,24 and 
increased screening and greater opportunity for diagnosis of comorbidities due to routine 
contact with healthcare providers among PLWH. However, the patterns of comorbidities among 
older PLWH are not well described.  
Understanding the co-occurrence of comorbidities is important because beyond the absolutely 
number of comorbidities, the interrelatedness of conditions impacts clinical complexity.7    
Therefore, I sought to identify classes of individuals based on patterns of non-HIV conditions 
among PLWH and compared them to HIV-negative individuals age ≥65 years using latent class 
analysis, a methodology that uses observed indicators to predict unobserved, latent classes of 
homogeneous groups within a heterogeneous population. I also investigated the association 
between sex and latent class membership, because most United States-based analyses of 





This analysis was conducted with administrative healthcare claims data from the IBM Watson 
Health MarketScan® Medicare Supplemental Database from 2009 to 2015. Enrollees in the 
database have Medicare supplemental insurance paid for by a former employer, in addition to 
traditional Medicare. The database includes inpatient and outpatient medical claims, outpatient 
pharmacy claims, and enrollment records. Individuals enter the database when their enrollment 
begins and exit when they disenroll or die. The database includes enrollees from all 50 states 
but is over-representative of the southern United States. 
The City University of New York School of Public Health Institutional Review Board granted this 
study Institutional Review Board exemption.  
Selection of PLWH and HIV-Negative Cohorts 
The PLWH cohort included individuals with (a) ≥2 non-diagnostic claims with an ICD-9-CM 
diagnosis of HIV (042, 795.71, V08, 079.53) in any position (primary or secondary) or (b) 1 non-
diagnostic claim with an HIV diagnosis and ≥1 claim for ART between January 1, 2010 and 
September 30, 2015. Claims with a procedure code for laboratory or radiology tests are 
considered diagnostic claims; all others are non-diagnostic. The service date on an individual’s 
most recent claim with an HIV diagnosis was referred to as the index date, in order to evaluate 
an individual at his or her oldest age in the database. 
Individuals with no claims with an HIV diagnosis and no claims for ART medications from 
January 1, 2009 to September 30, 2015 were classified as HIV-negative. A pseudo-index date 
(referred to as the index date) for HIV-negative individuals was randomly assigned based on the 
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distribution of calendar year for index dates among selected PLWH; it was not tied to any 
specific healthcare encounter.  
PLWH and HIV-negative individuals were further required to have 12 months of continuous 
enrollment in the database prior to their index date in order to evaluate the claims for non-HIV 
conditions and to be age ≥65 years at the start of the evaluation period, which was defined as 
the 12 months before and including the index date.  
Exposure 
The exposure was HIV status as defined above.  
Non-HIV conditions 
Medical claims occurring during the 12-month evaluation period were evaluated for the 
presence of ≥1 non-diagnostic claim with the relevant diagnosis or procedure code for the 
following non-HIV conditions: ischemic heart disease (including myocardial infarction, angina, 
and atherosclerosis), congestive heart failure, cardiac dysrhythmia, hypertension, dyslipidemia, 
non-rheumatic heart valve disorders, peripheral vascular disease, dementia, cerebrovascular 
disease, rheumatologic disease, osteoarthritis, osteoporosis, peptic ulcer disease/esophageal 
reflux, liver disease, hepatitis C, diabetes, hemiplegia/paraplegia, kidney disease,  non-AIDS 
defining cancer, benign prostate hyperplasia, anemia, unspecified acquired hypothyroidism, 
glaucoma, cataract, retinal disorders (including non-diabetic retinopathy, and retinal or macular 
degeneration), anxiety, depression, schizophrenia, bipolar disorder, substance abuse, and 
tobacco use disorder. The conditions were chosen based on those included in the Deyo 
Charlson Comorbidity Index, a commonly used measure of comorbidities,30 and other analyses 
of comorbid conditions.3,4,20,31-33 The number of non-HIV conditions present was calculated 




Age in years at index date, sex, United States Census Bureau region,34 and urbanicity based on 
Metropolitan Statistical Areas35 based on enrollment information were examined as covariates 
and used to create a matched sample of HIV-negative individuals as described below.  
Analysis 
The conceptual foundation of the latent class methodology is that in a heterogeneous 
population, units within that population may be grouped into “latent” or unobserved 
homogeneous classes, based on similar patterns of observed indicators, known as items.36 The 
latent class model estimates the probability of membership in a latent class (γ), which describes 
class prevalence, and item-response probabilities (ρ), which describe class profile.36 For this 
analysis, units were individuals, items were non-HIV conditions, and item-response probabilities 
were interpreted as the probability of an individual in a given class having the specific non-HIV 
condition. Multiple group latent class models can assess group differences both in item-
response probabilities (ρ) and/or latent classes prevalence (γ).36 Model comparison involves 
fitting of a series of nested models specified using parameter restrictions.36 Finally, the model 
can adjust for covariates and estimate the association between covariates (β) and class 
membership using polytomous logistic regression.36  
Latent class analysis was used to determine classes of individuals based on the presence of 
non-HIV conditions among PLWH and HIV-negative individuals. Because of differences in the 
demographics between the cohorts, a subset of the HIV-negative cohort was matched to the 
PLWH cohort by the available demographic characteristics using an exact 10:1 match.  
First, separate latent class models were fit to each cohort (PLWH, HIV-negative, and matched 
HIV-negative) to assess whether the number of classes and the item-response probabilities for 
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each non-HIV condition were similar.36 The non-HIV conditions evaluated were limited to those 
that were present in ≥15% of the PLWH cohort to reduce the number of conditions analyzed and 
maximize statistical power. I used 500 random starts for each model to avoid model 
convergence to local rather than global maxima. The optimal number of latent classes was 
determined by Akaike information criterion (AIC), Bayesian information criterion (BIC), 
consistent AIC (CAIC), adjusted BIC (ABIC), and entropy,36 clinical and epidemiological 
knowledge, and interpretability of the classes. Lower values of AIC, BIC, CAIC, and ABIC and 
higher values of entropy were preferred.36 Each class was described based on the conditions 
which had approximately ≥0.5 probability of being present among the individuals in that class.37 
Individuals were assigned to a class based on the highest posterior probability of membership.38 
For each class, a mean posterior probability of ≥0.70 was considered good model fit.28,39 
Second, I fit two multigroup latent class models (PLWH plus all HIV-negative individuals and 
PLWH plus matched HIV-negative individuals) with HIV status as a grouping variable to test for 
measurement invariance (i.e., that the item-response probabilities do not vary by HIV status).36 I 
fit one model where item-response probabilities were allowed to vary (non-invariance) and a 
second nested model where item-response probabilities were constrained to be equal across 
groups (full invariance), and then compared the models using likelihood ratio tests.36 
Additionally, AIC and BIC were evaluated, because the p-value from the likelihood ratio test 
should be interpreted cautiously when a large number of item-response probabilities are 
estimated.36 As discussed in the results section, measurement non-invariance was found in the 
multigroup models and therefore, PLWH and HIV-negative individuals could not be included in a 
single model. Separate final models of the three cohorts were adjusted for age, sex, region, and 
urbanicity; however, differences between cohorts were not addressed by this statistical 
adjustment. I evaluated the association of sex and latent class membership using polytomous 
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logistic regression within the separate latent class models. Additionally, the proportions of 
individuals assigned to each class were stratified by sex and compared using chi-squared tests. 
Analyses were conducted with SAS 9.4 using the PROC LCA procedure.38 P-values <0.05 were 
considered statistically significant. 
I also grouped non-HIV conditions using cluster analysis as described in Appendix 2. 
RESULTS 
Description of cohorts 
Analyses included 2,359 PLWH and 2,010,513 HIV-negative individuals who met my eligibility 
requirements (Appendix 2 Figure 1). As of the index date, PLWH were approximately 5 years 
younger on average than unmatched HIV-negative individuals and a larger proportion of the 
cohort were men (p-values<0.001; Appendix 2 Table 1). The proportions of individuals residing 
in the South and living in an urban area were larger among PLWH compared to unmatched HIV-
negative individuals (p-values<0.001). The distributions of these characteristics were, by 
definition, identical for the matched cohorts.  
The PLWH cohort had a higher number of non-HIV conditions than the unmatched HIV- cohort 
(mean 4.61 [median 4] for PLWH vs. 3.94 [4] for HIV-negative) and the matched HIV-negative 
cohort (mean 3.57 [median 3] for HIV-negative; p-values<0.001; Appendix 2 Table 2). The most 
prevalent conditions in both cohorts were hypertension and dyslipidemia. Several conditions, 
including anemia, depression, kidney disease, and hepatitis C, were more common among 
PLWH. The difference in prevalence of benign prostate hyperplasia reflects the difference in sex 
distribution between the PLWH and unmatched HIV-negative cohorts. In all three cohorts, most 
individuals (86.3%, 79.5%, and 75.9% of PLWH, all HIV-negative, and matched HIV-negative 
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individuals; p-values<0.001) had ≥2 non-HIV conditions and the number of conditions increased 
with age (Figure 1).  
Number of latent classes 
For PLWH, the optimal number of classes was between three and five (Figure 2A, Appendix 2 
Table 3). For both HIV-negative cohorts, a 3-class solution was appropriate, as was a 5-class 
solution for the matched HIV-negative cohort (Figures 2B and C, Appendix 2 Table 3). Based on 
the fit statistics, lower posterior probabilities for some classes in the 4- and 5- class solution 
(Appendix 2 Table 4), and similar interpretation among the 3, 4 and 5-class models, I chose a 3-
class solution for all three cohorts. The three latent classes were similar between the PLWH and 
both HIV-negative cohorts (Appendix 2 Table 5). Class 1 had item-response probabilities that 
were approximately ≥0.50 for ischemic heart disease, cardiac dysrhythmia, hypertension, 
dyslipidemia, diabetes, and anemia. This class was termed the sickest in comparison to the 
other two classes. Class 2 was characterized by high probabilities of hypertension and diabetes 
but lower probabilities of the other conditions; and the final class, the healthiest, had item-
response probabilities <0.50 for all conditions analyzed. Mean posterior probabilities were ≥0.70 
for all classes.  
Multigroup latent class models 
Next, I fit multigroup latent class models for the PLWH plus HIV-negative cohorts to test for 
measurement invariance by HIV status. The likelihood ratio tests were statistically significant 
and the fit statistics were generally lower with non-invariance, suggesting that there were 
differences in the item-response probabilities by HIV status. Therefore, the cohorts could not be 
combined into a single population (Appendix 2 Table 6). The item-response probabilities for 
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ischemic heart disease, hypertension, dyslipidemia, kidney disease, depression, and anemia 
were higher for PLWH than the HIV-negative cohorts (Appendix 2 Table 7).  
Final adjusted latent class models 
Due to the evidence of measurement non-invariance, I fit separate models for three cohorts in 
the adjusted analysis. While demographic characteristics were included as covariates in each 
individual latent class model, because the models were run separately for each cohort, the 
differences in the distributions of the demographic variables between the cohorts of PLWH and 
HIV-negative individuals persisted (e.g., the unmatched HIV-negative cohort was older and a 
larger proportion was female compared to PLWH).  
When comparing PLWH and unmatched HIV-negative individuals, I found similar probabilities 
for several conditions among the sickest classes; however, the probabilities of other conditions, 
like kidney disease and anemia, were higher among PLWH (Figure 3A). In the classes 
characterized by hypertension and dyslipidemia, the probabilities of most conditions were 
similar, with differences noted in ischemic heart disease and anemia, which were higher among 
PLWH. When comparing the healthiest classes, the probabilities of ischemic heart disease, 
cardiac dysrhythmia, chronic pulmonary disease, and cataracts were similar between PLWH 
and HIV-negative individuals, but for the remaining conditions, the probabilities were slightly 
higher for PLWH than their HIV-negative counterparts. The findings were similar when 
comparing PLWH and matched HIV-negative individuals (Figure 3B). 
Based on their maximum posterior probability, nearly 20% of the PLWH were assigned to the 
sickest group compared to 23.5% of the unmatched HIV-negative cohort (p<0.001) and 10.5% 
of the matched HIV-negative cohort (p<0.001). Approximately one-third of PLWH and 
unmatched HIV-negative individuals were assigned to hypertension and dyslipidemia compared 
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to one-half of matched HIV-negative individuals (p<0.001). A larger proportion of men than 
women were assigned to the sickest class among HIV-negative individuals (all HIV-
negative=29.7% vs. 18.5%; matched HIV-negative=11.4% vs. 6.7%, p<0.001), while the 
proportion of women assigned to the sickest class were larger than men among PLWH (18.24% 
vs. 22.47%, p=0.001; Figure 4). In the regression models of HIV-negative individuals, males 
were more likely to be in the hypertension/dyslipidemia class than the healthiest class compared 
to females, although the magnitude was small (all HIV-negative odds ratio [OR]=1.03, 95% CI 
1.02-1.05; matched HIV-negative OR=1.23, 95% CI 1.10-1.37), and males were over twice as 
likely to be in the sickest class than the healthiest class compared to females (all HIV-negative 
OR=2.23, 95% CI 2.20-2.25; matched HIV-negative OR=2.30, 95% CI 1.92-2.76; Table 1). The 
association between sex and latent class membership was not significant for PLWH.  
DISCUSSION 
In this retrospective, claims-based cohort analysis of Medicare enrollees, I found similar latent 
classes based on non-HIV conditions among older PLWH and HIV-negative persons: a class 
characterized by high probabilities of several conditions including ischemic heart disease, 
cardiac dysrhythmia, hypertension, dyslipidemia, diabetes, and anemia, a class primarily 
characterized by hypertension and dyslipidemia, and a class that was generally healthier. 
However, I observed differences in the probabilities of certain non-HIV conditions by HIV status, 
such as kidney disease and anemia among the sickest classes. When compared to a matched 
sample of HIV-negative individuals, a greater proportion of PLWH were assigned to the sickest 
class.  
Although many analyses have reported that PLWH have a greater number of comorbid 
conditions than HIV-negative individuals, only a small number of analyses have attempted to 
describe patterns of comorbidities among PLWH. One analysis by Goulet et al classified 
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comorbidities into three very broad clusters using factor analysis: mental disorders, medical 
disorders, and alcohol-related complications40 and an analysis by Kim et al. identified a 
metabolic condition cluster, a behavioral condition cluster, and a substance use cluster using a 
variation of factor analysis.41 In both analyses, the majority of the PLWH analyzed were not 
elderly (median age 47 and mean age 44 years old),40,41 and therefore, likely had a lower 
prevalence of multimorbidity than the individuals in my analysis. The mean and median age of 
PLWH in my study was 71 and 70 years, respectively. Additionally, these analyses clustered 
conditions, not individuals, so groups of healthy individuals could not be identified. 
I applied latent class analysis to identify classes based on non-HIV conditions. While several 
other methods have been used to describe disease co-occurrence, including observed versus 
expected frequencies of disease doublet or triplets, cluster analysis, and factor analysis, latent 
class analysis has been used in other analyses among non-HIV infected populations that aimed 
to describe classes of individuals based on the presence of health conditions and is gaining 
recognition in the epidemiological community. Latent class analysis has the advantage that the 
researcher does not need to specify the number of conditions in each cluster and is appropriate 
to cluster individuals using binary variables. This methodology has been used to describe 
comorbidity classes among Australians age ≥50,25 Danish adults age ≥16,26 Spanish adults age 
≥50,28 Aboriginals and non-Aboriginal Caucasian populations in Canada,42 jail detainees in 
residential psychiatric treatment,43 and Iraq and Afghanistan war veterans.44 While the latent 
class analyses can be difficult to compare across studies because of the different populations, 
conditions, and number of classes used, in most analyses, >50% of individuals were classified 
into a relatively healthy group with a minimal number of health conditions.25,26,28,43,44 I found that 
between 39% and 49% of individuals were in the healthiest class, depending on the cohort. 
Most relevant to my study are latent class analyses of multimorbidity patterns by Swartz, who 
evaluated the impact of HIV among men who have sex with men,29 and by Whitson et al, who 
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focused on the general population of Medicare enrollees age ≥65.27 Swartz identified two 
classes, one with low probabilities of chronic conditions and one with moderate to high 
probabilities of chronic conditions, and found that the probabilities of certain conditions differed 
by HIV status.29 Among individuals in the moderate to high probabilities group, the probabilities 
of having chronic back pain and hypertension were higher among HIV-negative men than HIV-
positive men, while the probabilities of liver problems, pancreatitis, other stomach and digestive 
problems, and skin problems were higher among HIV-positive men.29 Among individuals in the 
low probabilities group, the probabilities of liver problems and skin problems were higher for 
HIV-positive than HIV-negative men.29 Whitson et al identified six classes of elderly Medicare 
enrollees.27 One was described as the minimal disease class which comprised 33% of the 
population, and one was the very sick class which comprised 8%. Over 50% of individuals in the 
minimal disease class were male compared to only 38.5% of the very sick class. This is 
opposite of my finding, that being male was associated with membership in the sickest class 
among all HIV-negative individuals. This may be due to differences in the conditions included in 
the analyses and differences in data collection (self-report vs. claims). 
The proportion of the unmatched HIV-negative cohort assigned to the sickest class was greater 
than the proportion of PLWH assigned to that class, although the proportion of the matched 
HIV-negative cohort classified as sickest was smaller than that of PLWH. The difference in 
proportions between PLWH and unmatched HIV-negative cohorts likely reflects the contribution 
of HIV, the contributions of age and sex, which differed substantially between the two groups, 
and unmeasured variables; whereas the difference in proportions between PLWH and the 
matched HIV-negative group reflects the effect of HIV-related factors, as well as unmeasured 
variables that were uncontrolled after matching. The probability of having a certain non-HIV 
condition was higher for PLWH than HIV-negative individuals in the same class. For example, 
among individuals in the sickest class, diabetes, kidney disease, depression, and anemia were 
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more common among PLWH than HIV-negative individuals, which is consistent with other 
analyses.11,13,16,17,20,45-47 The increased risk for non-HIV conditions among PLWH may be 
attributed to chronic inflammation and immune compromise due to the virus itself, side effects of 
ART, such as anemia, lipodystrophy, and renal impairment, ART non-adherence, or the higher 
prevalence of traditional risk factors for certain chronic conditions among PLWH.23,24,48 Also, 
PLWH have more contact with healthcare providers than HIV-negative individuals which may 
result in more frequent screenings for and earlier diagnosis of non-HIV conditions. 
Individuals with multimorbidity, like those in the sickest class in this analysis, are clinically 
complex due to the absolute number of health conditions but also to the interrelatedness of 
health conditions.7 For providers, challenges include adequately addressing all conditions 
during short office visits, managing conditions that are diverse in terms of etiology or severity, 
given the lack of clinical guidance for managing multimorbidity, avoiding drug-drug interactions 
and contraindications,7 and the coordination and cooperation of many subspecialties,8 including 
infectious disease healthcare practitioners, primary care providers, specialist providers, and 
geriatricians. For patients, challenges include interacting with many providers49 and being 
adherent to treatment recommendations, including pharmacotherapy for multiple conditions at 
the same time. Both multimorbidity and polypharmacy have been associated with decreases in 
ART adherence50,51 and the number of comorbid conditions has been associated with 
decreases in quality of life.52,53 
This analysis has limitations. First, administrative healthcare claims are generated for billing 
purposes, not for research, and coding errors may be present. Conditions will be under-
estimated if an individual did not seek care for the condition. Diagnoses made during healthcare 
services covered by other insurance plans, such as Medicaid, or paid for out-of-pocket are not 
included in this database. HIV status was inferred from claims based on diagnoses and ART 
medication use. Misclassification may have occurred if individuals in the HIV-negative cohort 
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had undiagnosed HIV. However, especially in this age group, the proportion of undiagnosed 
individuals is likely very small relative to my total number of HIV-negative individuals and, 
therefore, is unlikely to have affected my conclusions. While diagnosis codes exist for substance 
abuse and tobacco use disorder, the conditions are likely under-coded and therefore, their 
prevalence may be underestimated. Second, race, socioeconomic status, and lifestyle 
behaviors are not available in claims data and therefore, could not be used as matching criteria. 
Third, the individuals analyzed had Medicare Supplemental insurance and may have higher 
socioeconomic status and more generous medical and pharmacy benefits than other elderly 
PLWH and HIV-negative individuals. The most vulnerable PLWH are likely not included in my 
study and therefore, I may be underestimating the true differences between elderly PLWH and 
HIV-negative individuals. The number of older HIV-positive women included in this analysis was 
small and more research is needed to examine patterns of comorbidities in this group of 
individuals. Lastly, latent class analysis is a type of regression analysis which is affected by 
sample size, the number of items, and the specific items included. The class assignment is 
probabilistic rather than deterministic. A different set of conditions may have resulted in a 
different number of classes, greater differentiation between the classes, or better model fit. 
In conclusion, I identified three underlying classes of elderly PLWH and HIV-negative individuals 
based on the presence of non-HIV conditions: a class characterized by many conditions, a class 
characterized by hypertension and dyslipidemia, and a class characterized by lower 
probabilities of non-HIV conditions. Compared to demographically matched HIV-negative 
individuals, a larger proportion of PLWH were part of the sickest class of individuals, with higher 
probabilities of certain conditions, such as kidney disease and anemia. An understanding of the 
patterns of comorbid disease may help target interventions aimed at improving the overall 
health of elderly PLWH. Resources related to clinical management may be focused towards the 
49 
 
individuals with multiple serious comorbidities while interventions focused on primary and 
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CHAPTER 3 TABLES AND FIGURES 
Chapter 3 Figure 1. Proportion of individuals with 0, 1, 2, and 3+ non-HIV conditions, stratified by age group 
 
Abbreviations: HIV, human immunodeficiency virus; PLWH, people living with HIV. 
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Abbreviations: ABIC, adjusted Bayesian information criterion; CAIC, consistent Akaike information criterion; HIV, 
human immunodeficiency virus.; PLWH, people living with HIV.
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Abbreviations: HIV, human immunodeficiency syndrome; HTN/DYS; hypertension/dyslipidemia; PLWH, people living with HIV. 




Chapter 3 Figure 4. Assigned Class for Separate Adjusted* Latent Class Models 
 
Abbreviations: HIV, human immunodeficiency syndrome; HTN/DYS; hypertension/dyslipidemia; PLWH, people living 
with HIV. 
*The three separate latent class models were adjusted for age, sex, region, and urbanicity. 
Note: p-values comparing PLWH vs. all HIV-negative and PLWH vs. matched HIV-negative were <0.001. p-value 
comparing men vs. women within the PLWH was 0.001. p-values comparing men vs. women within all HIV-negative 























Class Sickest vs. 
Healthiest 
  OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
            
                 
Sex                            
Male 1.24 0.81 1.90 1.04 0.73 1.48 1.03 1.02 1.05 2.23 2.20 2.25 1.23 1.10 1.37 2.30 1.92 2.76 
Female (ref) 1.00   1.00    1.00   1.00   1.00   1.00    
  
                           
Other Covariates                   
Age group           
                 
65-69 (ref) 1.00   1.00    1.00   1.00   1.00   1.00   
70-74 1.23 0.89 1.71 2.03 1.45 2.84 1.38 1.36 1.39 2.23 2.19 2.27 1.43 1.31 1.57 2.57 2.21 3.00 
75-79 1.67 0.97 2.88 4.51 2.90 7.01 1.48 1.45 1.50 4.49 4.41 4.58 1.57 1.36 1.81 4.76 3.97 5.72 
80-84 2.08 1.01 4.32 4.93 2.62 9.23 1.12 1.10 1.14 6.89 6.75 7.03 1.32 1.06 1.64 5.64 4.47 7.12 
85+ 0.58 0.07 4.69 10.96 5.51 21.81 0.51 0.49 0.52 8.54 8.37 8.72 1.10 0.80 1.52 10.28 7.91 13.37 
  
                           
Region                            
Northeast (ref) 1.00   1.00    1.00   1.00   1.00   1.00    
North Central 0.87 0.53 1.45 1.54 1.02 2.33 0.76 0.75 0.77 1.03 1.02 1.05 0.82 0.72 0.93 1.05 0.89 1.24 
West 0.75 0.51 1.11 0.89 0.62 1.27 0.77 0.76 0.78 0.85 0.84 0.87 0.89 0.81 0.99 0.78 0.67 0.91 
South 0.85 0.58 1.26 0.51 0.33 0.79 0.58 0.57 0.59 0.59 0.58 0.60 0.55 0.50 0.61 0.50 0.42 0.59 
  
                           
Urbanicity                            
Urban (ref) 1.00   1.00    1.00   1.00   1.00   1.00    
Rural 0.80 0.42 1.53 0.65 0.35 1.19 0.95 0.93 0.96 0.87 0.86 0.88 0.93 0.78 1.09 0.93 0.73 1.19 
Individuals with missing region or urbanicity were excluded (n excluded for PLWH = 21, for all HIV-negative = 9,377, for matched HIV-negative =210). 




*p-values from Type III tests for PLWH: male vs. female = 0.594; all age groups vs. 65-69 <0.001; North Central vs. Northeast = 0.060, West vs. Northeast = 
0.341, South vs. Northeast = 0.006; rural vs. urban = 0.340. 
**p-values from Type III tests for all HIV-negative individuals were all <0.001. 
***p-values from Type III tests for matched HIV-negative individuals were all <0.001 except: North Central vs. Northeast = 0.005, West vs. Northeast = 0.002; rural 
vs. urban = 0.588. 
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Chapter 4: The Association Between Comorbidity and Comedication Burden and 




Adherence to antiretroviral therapy (ART) improves survival for people with HIV (PLWH). 
However, non-HIV comorbidities, which are common among elderly PLWH, may negatively 
impact ART adherence. I examined the impact of comorbid disease and comedication burden 
on ART adherence among PLWH age ≥65 years living in the US. I selected 1,644 PLWH based 
on the presence of ≥1 medical claim with a diagnosis of HIV and ≥1 outpatient pharmacy claim 
for ART in the IBM MarketScan® Medicare supplemental insurance claims database from 2010 
to 2015. The most recent ART claim with 12 months of follow-up was selected as the index 
date. The number of comorbidities was counted based on claim diagnoses during the 12-month 
pre-period. The pre-period number of daily comedications was calculated by summing values in 
the days’ supply field from all non-ART pharmacy claims (including acute and chronic 
medications) during the pre-period and dividing by 365. Both the comorbidity and non-ART 
medication variables were categorized using quartiles of their distributions. PLWH were also 
assigned to a comorbidity class using latent class analysis. Individuals were classified as 
adherent to ART if they had ≥3 antiretroviral medications on ≥80% of days during the 12-month 
follow-up period. Logistic regression models were fit adjusting for demographic and clinical 
covariates. The mean age of PLWH was 71 years and 82% were male. The average numbers 
of comorbidities and comedications were 4.0 and 3.9, respectively. Approximately 60% of 
PLWH were adherent to ART. Having 5-6 comorbid conditions compared to 0-2 (adjusted odds 
ratio [AOR]=1.420, 95% confidence interval [CI] 1.035-1.947, p=0.030) and being a member of 
the hypertension/dyslipidemia/diabetes class vs. the healthiest class (AOR=1.319, 95% CI 
1.047-1.661 p=0.019) were associated with a greater likelihood of non-adherence. When the 
number of comedications was included in the model, PLWH with 5-6 comorbid conditions 
(AOR=1.589, 95% CI 1.131-2.232, p=0.008) and PLWH with ≥7 conditions (AOR=1.528, 95% 
CI 1.049-2.225, p=0.027) were 50%-60% more likely to be non-adherent than PLWH with 0-2 
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conditions. Among PLWH ≥65 years old, I found evidence of a negative impact of comorbid 
disease on ART adherence, which increased when controlling for comedications. This suggests 





With the widespread use of effective and tolerable antiretroviral therapy (ART) in the United 
States, many of the estimated 1.1 million people with HIV (PLWH) are living into old age.1 To 
experience the clinical, immunological and survival benefits of ART, patients must be adherent 
to their medications.2-4 Several factors may influence medication adherence, including non-HIV 
comorbidities affecting older PLWH, and the accompanying comedication burden.5.6 Research 
has shown that older PLWH are at higher risk for comorbid conditions at earlier ages than their 
HIV-negative counterparts and have greater overall comorbid disease and comedication 
burden.7-11 
Most analyses of comorbidities and ART adherence have focused on mental health conditions, 
while there is less research on non-psychiatric, aging-related comorbidities and overall 
comorbidity burden. The association of depression, which affects more than half of PLWH aged 
50 or older,12 with ART adherence is perhaps the most studied relationship. In a systematic 
review, depression was both highly prevalent and associated with poorer ART adherence in 30 
of 52 studies.5 Some studies have also attempted to evaluate the association between ART 
adherence and cognitive impairment, including HIV-associated neurocognitive disorder (HAND), 
with mixed results.13-16 Comorbidities that require daily medications may be particularly 
important, as a large number of comedications (polypharmacy) may cause lower overall 
medication adherence, including lower ART adherence.6 However, results from qualitative 
research indicates that PLWH with comorbid conditions may prioritize their ART over 
medications for their other chronic conditions because they feel that ART is more necessary.17  
To date, few analyses have focused on the population of elderly PLWH which is growing the 
United States. Therefore, the objective of this paper was to evaluate the association between 
several measures of comorbid disease and comedication burden, including number of comorbid 
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conditions, classes of comorbidity, and number of daily comedications, with ART adherence 
among Medicare enrollees with HIV aged ≥65 years. 
METHODS 
Data Sources 
Elderly PLWH included in these analyses were selected from the IBM Watson Health 
MarketScan® Medicare Supplemental and Coordination of Benefits Database, a proprietary 
administrative healthcare claims database, comprising healthcare claims for over 9 million 
covered lives from 1995 to 2015. In this database, enrollees are insured through Medicare 
supplemental insurance plans paid for by former employers. The data include enrollee 
demographic and enrollment information, inpatient and outpatient medical claims, and 
outpatient pharmacy claims.  
The CUNY SPH Institutional Review Board granted this study IRB exemption. The MarketScan 
database satisfies the conditions set forth in Sections 164.514 (a)-(b)1ii of the Health Insurance 
Portability and Accountability Act of 1996 privacy rule regarding the determination and 
documentation of statistically de-identified data. All data were previously collected. 
Patient Selection 
Individuals with ≥1 non-diagnostic claim with an ICD-9-CM diagnosis of HIV (042, 795.71, V08, 
079.53) in any position (primary or secondary) and ≥1 claim for ART between January 1, 2010 
and September 30, 2015 were selected from the database. The date on a patient’s most recent 
ART claim after which he or she had ≥12 months of continuous enrollment was defined as the 
index date. The 12-month period after the index date was known as the follow-up period. 
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Patients were also required to have ≥12 months of continuous enrollment prior to the index date 
(12-month pre-period) and be ≥65 years or old at the start of the pre-period. 
Exposures of Interest 
I explored four exposures of interest: (1) the total number of comorbid conditions, (2) the total 
number of daily non-ART medications, referred to as “comedications”, (3) a combined 
comorbidity/comedication burden variable, and (4) the assigned comorbidity class based on 
latent class models.  
1. Total number of comorbid conditions: I evaluated claims during the pre-period for the 
presence of diagnosis or procedure codes for 32 non-HIV conditions, including ischemic 
heart disease, hepatitis C, diabetes, cancer, anxiety, depression, substance abuse, and 
tobacco use disorder. The list of conditions evaluated was based on the Deyo Charlson 
Comorbidity Index,18 which is a measure of comorbidity often used in claims-bases 
analyses, common diagnoses of elderly individuals in this dataset, and other analyses of 
comorbidities.7,8,10,19-21 The non-HIV conditions have been described in detail earlier (see 
Chapter 2, page 13). To evaluate a dose response, individuals were categorized into 
one of four groups based on quartiles of the distribution of number of comorbid 
conditions: 0-2, 3-4, 5-6, and ≥7. 
2. Total number of daily non-ART comedications: To calculate the number of daily 
comedications, the days’ supply fields on all non-ART outpatient pharmacy claims during 
the pre-period were summed and the sum was divided by 365 days. Non-ART 
medication claims could be for acute (e.g., a 10-day course of antibiotics) or chronic 
(e.g., treatment for hypercholesterolemia) use. To evaluate a dose response, individuals 
were categorized into one of four groups based on quartiles of the distribution of number 
of daily comedications: ≤1.6, >1.6-3.4, >3.4-5.6, and >5.6. 
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3. Combined comorbidity/comedication variable: A 4-level ordinal categorical variable was 
created: few comorbidities/few comedications, many comorbidities/few comedications, 
few comorbidities/many comedications, and many comorbidities/many comedications, 
based on the median number of comorbidities and comedications (4 and 3.4, 
respectively). 
4. Comorbidity classes: Comorbidity classes were determined by latent class analysis 
(LCA) using the aforementioned conditions that were prevalent in ≥15% of sample. Use 
of the latent class methodology in this patient population has been described in detail 
elsewhere (see Chapter 3), but briefly, non-HIV conditions were used to determine 
underlying classes of non-HIV comorbidity patterns within individuals. I evaluated both a 
3-class and a 4-class solution. In the 3-class solution, there was a healthy class where 
no conditions had probabilities of >0.50, a class categorized by hypertension, 
dyslipidemia, and diabetes, and a less common class (4.08%) categorized by 
hypertension, dyslipidemia, glaucoma, and cataracts (Appendix 3 Table 1). In the 4-
class solution, there was a healthy class, a class categorized by hypertension and 
dyslipidemia, a class categorized by hypertension, dyslipidemia, and cataracts, and 
finally the sickest class (12.35%) categorized by hypertension, dyslipidemia, diabetes, 
ischemic heart disease, and renal disease. Patients were assigned to one class based 
on posterior probabilities. Analyses were conducted were performed using the PROC 
LCA procedure developed at Pennsylvania State University.22 
Outcome 
The primary outcome was ART adherence measured in the 12-month follow-up period and 
operationalized as proportion of days covered (PDC).23 PDC is a claims measure based on 
service dates and days’ supply fields on outpatient pharmacy claims with a National Drug Code 
for an antiretroviral medication and for this analysis, was equal to the number of days with ≥3 
68 
 
antiretroviral medications, excluding ritonavir which is a medication enhancer, during the follow-
up period divided by 365 days. Adherence to specific ART regimens was not measured 
because I was interested in overall adherence to ART. Therefore, the PDC can be interpreted 
as the proportion of days during follow-up when the individual filled enough prescriptions to 
have ≥3 antiretroviral medications on hand. Early refills of medications were appended to the 
days’ supply of prior prescription. Analyses were conducted using two cut-points for adherent 
vs. non-adherent: 80% (main analysis) and 95% (sensitivity analysis). Both cut-points are based 
on the published literature of HIV and chronic conditions.2-4 
Covariates 
The following demographic characteristics at the index date were based on enrollment 
information: age, sex, US Census Bureau region,24 and urbanicity based on residence in a 
Metropolitan Statistical Area.25 Additionally, the following characteristics were captured based 
on outpatient pharmacy claims for ART because they may impact adherence: binary flags for 
types of ART classes filled ±45 days around the index date, a binary flag for ≥1 claim for an 
ART single tablet regimen on the index date or during follow-up, a binary flag for ≥1 claim for 
ART filled via mail-order pharmacy (which generally supply more days of drug) on the index 
date or during follow-up, and pre-period ART PDC.  
Analyses 
Exposures and patient characteristics were stratified by the adherence outcome variable 
(yes/no) and compared using t-tests and chi-squared tests. To analyze the association between 
exposures and ART adherence, separate crude and adjusted logic regression models 
controlling for covariates were fit with one exposure per model. Additionally, a model was fit 
including both the number of comorbid conditions and the number of comedications. The 
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models estimated the odds ratios for non-adherence to ART medications comparing PLWH with 
increasing levels of baseline comorbidity/comedication exposure to PLWH with the lowest level 
of baseline comorbidity/comedication exposure as the reference.  
P-values less than 0.05 were considered statistically significant. Analyses were conducted with 
SAS 9.4 (Cary, NC).  
I also assessed the unadjusted association between comorbidity class and ART adherence 
accounting for the uncertainty of class assignment and whether the relationship between the 
number of comorbidities (above or below the median) and the number of comedications (above 
or below the median) and ART adherence was mediated by total patient out-of-pocket costs. 
These methods and results are discussed in Appendix 3. 
RESULTS 
Patient Sample 
A total of 3,927 PLWH met my inclusion criteria of having ≥1 claim with an HIV diagnosis and ≥1 
claim for ART in the Medicare Supplemental database between 2010 and 2015. After applying 
the remaining patient selection criteria, the final sample consisted of 1,644 PLWH (Figure 1). 
Overall, the mean age was 70.8 years and over 80% of individuals were between 65 and 74 
years old. Most individuals were male (82.4%; Table 1). 
The mean number of comorbid conditions was 4.0 and the mean number of daily non-ART 
medications was 3.9. For the combined comorbidity/comedication variable, approximately 40% 
of the population had both a number of comorbidities that was less than or equal to the median 
and a number of daily comedications that were less than or equal to the median (few 
comorbidities/few daily comedications) and 10% of the population had both a number of 
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comorbidities that was above the median and a number of daily comedications that was less 
than or equal to the median (many comorbidities/few daily medications). The most common 
comorbidities were hypertension (57.6%) and dyslipidemia (52.8%). In the pre-period, nearly all 
PLWH used ART and approximately 2/3 of patients (61.8%) had a pre-period PDC≥80%. The 
most common classes of ART filled around the index date were NRTIs (91.4%) and NNRTIs 
(54.0%). During the follow-up period, 42.2% of PLWH had ≥1 claim for a single tablet ART 
regimen and 37.5% filled an ART claim via mail-order pharmacy (Table 2). 
ART Adherence During the Follow-Up Period: Main Analysis 
Descriptive analysis. Using the 80% cut-off, 634 individuals (38.6%) were non-adherent during 
the 12-month follow-up period. Non-adherent individuals tended to be older (mean age 71.5 vs. 
70.4, p<0.001; Table 1). Non-adherent patients had more comorbidities on average (4.4 vs. 3.8, 
p<0.001) with 20.0% of non-adherent PLWH having ≥7 comorbidities compared to 14.5% of 
adherent PLWH (p=0.001). There was no significant difference in the number of average daily 
comedications between non-adherent patients and adherent patients (3.8 vs. 4.0, p=0.217). A 
larger proportion of non-adherent patients were categorized as having many comorbidities and 
few comedications compared to adherent patients (20.2% vs. 7.3%, p<0.001). Large differences 
were also noted in the proportion patients with few comorbidities/few comedications (non-
adherent=61.6% vs. adherent=32.9%, p<0.001) and many comorbidities/many comedications 
(non-adherent=48.5% vs. adherent=20.0%, p<0.001). For comorbidity classes, more non-
adherent than adherent PLWH were in the hypertension/dyslipidemia/diabetes class (55.4% vs. 
45.3%, p<0.001) in the 3-class solution and a greater proportion of non-adherent PLWH were in 
the hypertension/dyslipidemia class (45.3% vs. 38.4%) and fewer were in the healthiest class 
(22.7% vs. 28.9%, p<0.001) in the 4-class solution. Mean pre-period PDC was lower in patients 
who were classified as non-adherent to ART than patients who were classified as adherent to 
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ART in the follow-up period (51.8% vs. 80.8%, p<0.001). Fewer non-adherent patients filled a 
single tablet regimen than adherent patients (29.7% vs 50.0%, p<0.001; Table 2). 
Modeling. In separate adjusted models, PLWH with 5-6 comorbidities were significantly more 
likely to be non-adherent than PLWH with 0-2 comorbidities (AOR=1.420, 95% CI 1.035-1.947, 
p=0.030) and PLWH belonging to the hypertension/dyslipidemia/diabetes comorbidity class 
were significantly more likely to be non-adherent than PLWH in the healthiest class 
(AOR=1.319, 95% CI 1.047-1.661, p=0.019). In the adjusted model with both the number of 
comorbid conditions and the number of comedications as separate exposure variables, patients 
with 5-6 comorbid conditions (AOR=1.589, 95% CI 1.131-2.232, p=0.008) and patients with ≥7 
conditions (AOR=1.528, 95% CI 1.049-2.225, p=0.027) were 50%-60% more likely to be non-
adherent than patients with 0-2 conditions. All other results did not reach statistical significance 
(Figure 2A and 2B). 
ART Adherence During the Follow-Up Period: Sensitivity Analysis 
Descriptive analysis. Using the 95% cut-off, 971 individuals (59.1%) were non-adherent. 
Comparisons of the demographics and clinical characteristics between non-adherent and 
adherent PLWH using the 95% cut-off were similar to those using the 80% cut-off (Appendix 3 
Table 2 and 3). 
Modeling. In separate adjusted models using the 95% cut-off and both the number of comorbid 
conditions and the number of comedications included as exposure variables, patients with 5-6 
comorbid conditions (AOR=1.540, 95% CI 1.107-2.143, p=0.011) and patients with ≥7 
conditions (AOR=1.600, 95% CI 1.101-2.324, p=0.014) were approximately 50%-60% more 
likely to be non-adherent than patients with 0-2 conditions. In that same model, patients with 
>3.4-5.6 comedications (AOR=0.633, 95% CI 0.454-0.881, p=0.007) and with >5.6 
comedications (AOR=0.644, 95% CI 0.454-0.915, p=0.014) were significantly less likely to be 
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non-adherent compared to PLWH with ≤1.6 comedications. PLWH with few comorbidities and 
many comedications were significantly less likely to be non-adherent than PLWH with few 
comorbidities and few comedications (AOR=0.638, 95% CI 0.480-0.848, p=0.002). PLWH 
belonging to the hypertension/dyslipidemia/diabetes comorbidity class were significantly more 
likely to be non-adherent than PLWH in the healthiest class (AOR=1.313, 95% CI 1.049-1.644, 
p=0.017) and PLWH in the hypertension/dyslipidemia/diabetes/ischemic heart disease/renal 
disease class were significantly more likely to be non-adherent than PLWH in the healthiest 
class (AOR=1.503, 95% CI 1.010-2.237, p=0.045; Appendix 3 Figure 1A and 1B). 
Full models for both the 80% and 95% cut-offs can be found in Appendix 3 (Table 4 and Table 
5). 
DISCUSSION 
In this analysis of 1,644 PLWH age ≥65, approximately 60% individuals were adherent to ART, 
defined as having refilled enough medication to have ≥3 antiretroviral medications to take on 
80% of days during the 12-month follow-up period. This proportion dropped to 40% when a 95% 
cutoff was used. Having multiple comorbidities and multiple comedications was very common in 
this population, and I found evidence that comorbidity burden may negatively impact ART 
adherence. Compared to the group of individuals with the fewest comorbidities, there was a 
trend of increased odds of non-adherence with a greater comorbid disease burden. The 
magnitude of the association increased when the number of comedications was included in the 
same model. Additionally, membership in certain comorbidity classes, such as 
hypertension/dyslipidemia/diabetes compared to the healthiest class was also associated with 
non-adherence. Interestingly, PLWH who filled more comedications appeared to be more likely 
to be adherent to ART compared to the group of PLWH with the fewest daily comedications in 
the models controlling for the number of comorbidities. The associations were of borderline 
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statistical significance when 80% was used as a cutoff for adherence and significant when 95% 
was used. This result was contrary to my expectations as I hypothesized that both comorbidities 
and comedications would have a negative impact on ART adherence in elderly PLWH. 
 
Other published analyses have reported a negative association of specific comorbidities with 
ART medication adherence, like depression and HAND. While a consistent negative association 
has been found with depression and poor ART adherence,5 in several studies that investigated 
HAND and ART adherence among PLWH, temporality of exposure and outcome could not be 
established, and the results were mixed.13-16 The analyses of HAND highlight a challenge in 
studies of the impact of comorbidities on adherence. The relationship between adherence and 
any comorbidity, cognitive impairment for example, could flow in either direction – poor 
adherence results in impairment and/or impairment results in poor adherence – or in a feedback 
loop, with cognitive impairment resulting in poor adherence which then results in increased 
impairment, which then results in poorer adherence, and so on. Regarding the total number of 
comorbidities, a study of PLWH aged 50-64 using Medicaid claims data found that compared to 
PLWH with no comorbidities, those with ≥3, 2, and 1 comorbidity had 33%, 14%, and 18% 
significantly lower odds of being adherent to ART (defined as a PDC≥95%), respectively.26 To 
my knowledge, no other analyses have analyzed the impact of combinations of comorbidities as 
I did with latent class analyses and therefore, more research is needed into the relationship 
between specific comorbid disease combinations and ART adherence. 
Many comorbidities require daily medications. Among the elderly population in general, 
polypharmacy has been associated with lower medication adherence.27  Among PLWH, a study 
conducted by Cantudo-Cuenca and colleagues in which study participants had a median age of 
47 years found that in unadjusted models, both multimorbidity and polypharmacy were more 
common among non-adherent PLWH; however, when including both multimorbidity and 
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polypharmacy in a single model, only polypharmacy was associated with poor ART adherence.6  
A second study by Manzano-Garcia et al. of PLWH (median age 48 years) evaluated the 
association between medication regimen complexity index, which incorporated all medications 
taken including ART, concomitant medications, and over-the-counter medications, dosing 
regimens, dosing forms, and comorbidities with ART adherence using electronic medical 
records.28 The authors reported that both greater medication complexity and greater number of 
comorbidities were independently associated with non-adherence to ART.28 
After controlling for the number of comorbid conditions, I found that the number of 
comedications tended to be inversely associated with ART adherence. When I analyzed a 
combination variable of comorbidities and comedications, I also found that PLWH with few 
comorbidities but many comedications had better ART adherence than PLWH with few 
comorbidities and few comedications in the 95% cutoff model. Based on clinical knowledge and 
published literature on polypharmacy and pill burden, I hypothesized that the odds of non-
adherence would increase as the number of comedications increased. The differences in my 
results compared to other published analyses may be due to differences in data sources and 
variable measurement. My analysis was a retrospective claims study based on insured PLWH 
and variables, including adherence, were based on filled prescription claims, whereas the other 
analyses relied on medical records and ART adherence was determined based on dispensing 
records and self-report of medication adherence. Patients also had to survive to age 65 to be 
eligible for my study; therefore, some individuals who were not adherent to ART or other 
medications may not have lived long enough to be included.   
Another potential explanation for the unexpected trend of comedication with ART adherence is 
that instead of capturing the impact of comedication burden on ART adherence, I am identifying 
a phenomenon where individuals who fill their prescriptions for non-ART medications are more 
likely to fill their ART prescriptions as well and are generally adherent. Other claims-based 
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analyses have reported similar findings regarding polypharmacy and medication adherence for 
other conditions. One analysis of individuals with type 2 diabetes found the higher pill burden as 
determined by pscreription claims, including both antidiabetes and comedications, was 
associated with better adherence to antidiabetes medications.29 Another analysis of women with 
breast cancer which used the MarketScan databases evaluated the impact of polypharmacy 
with lipid-lowering medications, antihypertensive medications, oral antidiabetes medications, 
insulins, antidepressants, anxiolytics, antipsychotics, and opioids on adherence to adjuvant 
endocrine therapy.30 Polypharmacy was associated with better adherence to adjuvant endocrine 
therapy with a dose response where more medications were associated with increasingly better 
odds of adherence.30 Additionally, while a diagnosis of depression is negatively associated with 
adherence, antidepressant treatment among PLWH with comorbid depression is associated 
with better ART adherence.5,21,32 PLWH with depression who are receiving antidepressants may 
be in more consistent contact with the health care system, resulting in better adherence. I may 
be detecting a similar effect in my analyses.  
I also found that pre-period adherence, mail-order pharmacy use, and use of a single tablet ART 
regimen were strongly associated with ART adherence during the follow-up period. These 
results were not surprising as prior adherence was hypothesized to be associated with current 
adherence and because mail-order pharmacy claims generally have a 90 days’ supply and 
therefore, patients have more medication on hand and the burden of physically obtaining the 
medication is lower. Interestingly, mail-order pharmacy was no longer significant when defining 
adherent as PDC≥95%. Many analyses have reported that reduced medication complexity and 
lower pill burden are associated with better adherence among patients with chronic 
diseases.33,34 These can be achieved through single tablet regimens. An analysis of factors 
associated with the use of single tablet ART regimens found that while prescribing single tablet 
regimens is more common in recent years, PLWH with polypharmacy or frailty were 
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substantially less likely to be prescribed a single tablet regimen.35 The authors hypothesize that 
providers may believe that single tablet regimens are less flexible, regarding drug-drug 
interactions, among clinically complex patients.35 More research is needed to examine the 
attitudes toward and impact of use of single tablet regimens among older populations of PLWH. 
The limitations of this analysis include those inherent to claims-based analyses. Administrative 
healthcare claims are generated for billing purposes, not for research. It is possible that 
incorrect codes were present. Adherence was based on service dates and days’ supply fields 
on outpatient ART claims that appeared in the database. ART procured through other means 
was therefore not reflected in the adherence calculation. While the individuals in this analysis 
filled their ART prescriptions, I do not know if they took the medications. However, several 
analyses have found that better adherence based on pharmacy/prescription-based adherence 
measures is associated with better viral suppression, indicating that ART was taken.2,36-38 I 
measured the proportion of days with ≥3 antiretroviral medication on hand. Adherence rates 
may have been lower if I had measured adherence to ART regimens (i.e., defining ART 
regimens and checking to see if an individual had every component of the prescribed regimen 
on hand on each day). Additionally, nearly all people in this analysis were continuing users of 
ART, not new initiators. Therefore, I started measuring ART adherence at the most recent 
prescription for which a patient had a subsequent 12 months of follow-up. While it is cleaner to 
measure adherence from the start of ART, the small sample size of new initiators in this age 
group precluded such an analysis. The number of comorbid conditions was based on diagnoses 
coded on claims. If an individual did not seek care for a condition or a diagnosis did not appear 
on the individual’s claims, the comorbidity could not be factored into this analysis. Similarly, 
comedications that did not result in a pharmacy claim, such as over the counter medications or 
written prescriptions that an individual did not fill, and comedications or ART paid for by another 
insurer were not included. Race, socioeconomic status, lifestyle behaviors, duration of HIV, or 
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laboratory measures like CD4 count and viral load are not available in claims data and 
therefore, could not be used as covariates in models or as proxies for adherence (i.e. viral load). 
Because individuals were primarily continuing ART users and HIV-specific characteristics are 
not available, it is possible the low ART adherence prior to or during the pre-period resulted in 
more comorbidity which then affected ART adherence during follow-up. Patients who died 
without meeting the continuous enrollment inclusion criterion, including those with severe 
comorbidities or advanced HIV/AIDS, were excluded.  
In conclusion, I found that PLWH age ≥65 with more comorbid conditions tended to be less 
adherent to ART than PLWH with fewer comorbidities, when adjusting for the number of 
comedications filled. I noted the opposite trend for comedications and ART adherence, when 
adjusting for the number of comorbidities, which should be explored further. As the population of 
PLWH ages and the proportion of PLWH with multimorbidity increases, primary prevention and 
management of comorbid conditions among elderly PLWH and ART adherence support are 
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CHAPTER 4 TABLES AND FIGURES  
Chapter 4 Figure 1. Patient attrition 
Individuals with Medicare Supplemental insurance with  
≥1 medical claim with a diagnosis code for HIV AND ≥1 




People Living with HIV 
 
≥12 months of continuous enrollment prior to index date 
 
N=2,863 (73%) 




≥12 months of continuous enrollment following ART 
claim 
 




Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency syndrome. 
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Chapter 4 Table 1. Demographic characteristics of elderly PLWH, stratified by ART adherence using 80% cut-off 
  ALL 
PATIENTS ADHERENT TO 
ART (PDC≥80%) 
PATIENTS NOT 
ADHERENT TO ART 
(PDC<80%) 
p-value 
  N= 1,644 N= 
1,010 
(61.4%) N= 634 (38.6%) 
 N/Mean %/SD N/Mean %/SD N/Mean %/SD 
Age (Mean, SD) 70.8 4.5 70.4 4.2 71.5 4.8 <0.001 
        
Age group (N, %)        
65-69 807 49.1% 540 53.5% 267 42.1% <0.001 
70-74 550 33. 5% 325 32.2% 225 35.5%  
75-79 194 11.8% 99 9.8% 95 15.0%  
80-84 67 4.1% 35 3.5% 32 5.0%  
85+ 26 1.6% 11 1.1% 15 2.4%  
        
Sex (N, %)        
Male 1,355 82.4% 844 83.6% 511 80.6% 0.124 
Female 289 17.6% 166 16.4% 123 19.4%  
        
Region (N, %)        
Northeast 463 28.2% 295 29.2% 168 26.5% 0.001 
North Central 245 14.9% 137 13.6% 108 17.0%  
West 500 30.4% 286 28.3% 214 33.8%  
South 426 25.9% 282 27.9% 144 22.7%  
Unknown 10 0.61% 10 1.0% 0 0.0%  
        
Urbanicity (N, %)        
Urban 1,545 94.0% 955 94.6% 590 93.1% 0.020 
Rural 92 5.6% 48 4.8% 44 6.9%  
Unknown 7 0.43% 7 0.7% 0 0.0%  
        
Index Year (N, %)        
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2010 64 3.9% 40 4.0% 24 3.8% <0.001 
2011 141 8.6% 90 8.9% 51 8.0%  
2012 296 18.0% 178 17.6% 118 18.6%  
2013 303 18.4% 183 18.1% 120 18.9%  
2014 136 8.3% 43 4.3% 93 14.7%  
2015 704 42.8% 476 47.1% 228 36.0%  
 
Abbreviations: PDC, proportion of days covered; PLWH, people living with HIV; SD, standard deviation.
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Chapter 4 Table 2. Clinical characteristics of elderly PLWH, stratified by ART adherence using an 80% cutoff 
  ALL 
PATIENTS ADHERENT TO 
ART (PDC≥80%) 
PATIENTS NOT 
ADHERENT TO ART 
(PDC<80%) 
p-value 
  N= 1,644 N= 1,010 (61.4%) N= 634 (38.6%) 
 
N/Mean/ 
Median %/SD N/Mean %/SD N/Mean %/SD 
Comorbidity (N, %)        
Number of comorbidities (Mean, SD) 4.0 2.8 3.8 2.7 4.4 2.9 <0.001 
Median, interquartile range 4 2-6 3 2-5 4 2-6  
        
Number of comorbidities: ≤2 553 33.6% 369 36.5% 184 29.0% 0.001 
Number of comorbidities: 3-4 479 29.1% 301 29.8% 178 28.1%   
Number of comorbidities: 5-6 339 20.6% 194 19.2% 145 22.9%   
Number of comorbidities: ≥7 273 16.6% 146 14.5% 127 20.0%   
        
Medications, including ART         
Number of daily medications** (Mean, SD) 5.7 3.4 5.8 3.4 5.4 3.3 0.015 
Median, interquartile range 5.0 3.1-7.6 5.2 3.3-7.7 4.8 2.9-7.4  
Comedications, not including ART         
Number of daily non-ART medications** (Mean, 
SD) 3.9 3.0 4.0 3.1 3.8 2.9 0.217 
Median, interquartile range 3.4 1.6-5.6 3.5 1.7-5.6 3.3 1.5-5.6  
        
Number of daily non-ART medications: ≤1.6 403 24.5% 236 23.4% 167 26.3% 0.530 
Number of daily non-ART medications: >1.6 to 
3.4 422 25.7% 265 26.2% 157 24.8%   
Number of daily non-ART medications: >3.4 to 
5.6 409 24.9% 258 25.5% 151 23.8%   
Number of daily non-ART medications >5.6 410 24.9% 251 24.9% 159 25.1%   
        
Comorbid Conditions/Comedications (N, %)        
   Few comorbidities/few daily  
   comedications 654 39.8% 410 32.9% 244 61.6% <0.001 
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   Many comorbidities/few daily  
   comedications 171 10.4% 91 7.3% 80 20.2%   
   Few comorbidities/many daily  
   comedications 378 23.0% 260 20.8% 118 29.8%   
   Many comorbidities/many daily  
   comedications 441 26.8% 249 20.0% 192 48.5%   
        
Comorbidities (N, %)        
Hypertension 947 57.6% 550 54.5% 397 62.6% 0.001 
Dyslipidemia 868 52.8% 532 52.7% 336 53.0% 0.898 
Diabetes 448 27.3% 264 26.1% 184 29.0% 0.201 
Cataract 408 24.8% 260 25.7% 148 23.3% 0.273 
Ischemic heart disease (Myocardial infarction, 
angina, atherosclerosis) 344 20.9% 192 19.0% 152 24.0% 0.016 
Kidney disease 270 16.4% 127 12.6% 143 22.6% <0.001 
Glaucoma 249 15.2% 166 16.4% 83 13.1% 0.066 
Chronic pulmonary disease 247 15.0% 128 12.7% 119 18.8% 0.001 
Cardiac dysrhythmia 242 14.7% 131 13.0% 111 17.5% 0.011 
Anemia 241 14.7% 120 11.9% 121 19.1% <0.001 
Benign prostate hyperplasia  227 13.8% 126 12.5% 101 15.9% 0.048 
Depression 213 13.0% 122 12.1% 91 14.4% 0.181 
Non-AIDS-defining cancer* 207 12.6% 119 11.8% 88 13.9% 0.212 
Osteoarthritis 179 10.9% 105 10.4% 74 11.7% 0.419 
Retinal disorders (including non-diabetic 
retinopathy, retinal or macular degeneration) 178 10.8% 109 10.8% 69 10.9% 0.954 
Peptic ulcer disease/esophageal reflux 159 9.7% 94 9.3% 65 10.3% 0.528 
Cerebrovascular disease 152 9.3% 88 8.7% 64 10.1% 0.346 
Heart valve disorders (non-rheumatic) 137 8.3% 86 8.5% 51 8.0% 0.737 
Peripheral vascular disease 116 7.1% 65 6.4% 51 8.0% 0.215 
Congestive heart failure 110 6.7% 51 5.0% 59 9.3% 0.001 
Substance abuse 103 6.3% 59 5.8% 44 6.9% 0.371 
Anxiety 98 6.0% 57 5.6% 41 6.5% 0.493 
Unspecified acquired hypothyroidism 95 5.8% 60 5.9% 35 5.5% 0.722 
Hepatitis C 86 5.2% 51 5.0% 35 5.5% 0.676 
Tobacco use disorder 71 4.3% 44 4.4% 27 4.3% 0.924 
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Osteoporosis 57 3.5% 33 3.3% 24 3.8% 0.576 
Dementia  50 3.0% 22 2.2% 28 4.4% 0.010 
Liver disease 43 2.6% 21 2.1% 22 3.5% 0.085 
Bipolar disorder 19 1.2% 11 1.1% 8 1.3% 0.750 
Rheumatologic disease 15 0.91% 12 1.2% 3 0.5% 0.138 
Hemiplegia/paraplegia 13 0.79% 9 0.9% 4 0.6% 0.562 
Schizophrenia (including schizoaffective 
disorder) 3 0.18% 2 0.2% 1 0.2% 0.852 
        
Comorbidity Class: 3-Class Solution        
Healthiest 768 46.7% 504 49.9% 264 41.6% <0.001 
Hypertension/Dyslipidemia/Diabetes 809 49.2% 458 45.3% 351 55.4%  
Hypertension/Dyslipidemia/Glaucoma/Cataracts  67 4.1% 48 4.8% 19 3.0%  
        
Comorbidity Class: 4-Class Solution        
Healthiest 436 26.5% 292 28.9% 144 22.7% <0.001 
Hypertension/Dyslipidemia  675 41.1% 388 38.4% 287 45.3%  
Hypertension/Dyslipidemia/Cataracts  330 20.1% 222 22.0% 108 17.0%  
Hypertension/Dyslipidemia/Diabetes/Ischemic 
Heart Disease/Renal Disease  203 12.3% 108 10.7% 95 15.0%  
        
Pre-Period ART Use (N, %) 1,544 93.9% 1,003 99.3% 541 85.3% <0.001 
PDC (Mean, SD) 69.6% 28.2% 80.8% 17.3% 51.8% 32.8% <0.001 
Median, interquartile range 77.4% 57.5%-90.8% 87.4% 73.4%-93.2% 57.5% 23.8%-81.1%  
PDC≥80% (N, %) 789 48.0% 624 61.8% 165 26.0% <0.001 
PDC≥95% (N, %) 236 14.4% 198 19.6% 38 6.0% <0.001 
        
ART Medication in Index Regimen 
(Prescriptions Filled ±45 Days around Index 
Date)** (N, %)        
NNRTI 888 54.0% 628 62.2% 260 41.0% <0.001 
PI 553 33.6% 290 28.7% 263 41.5% <0.001 
Fusion Inhibitor/Entry Inhibitor 39 2.4% 22 2.2% 17 2.7% 0.514 
Integrase Inhibitor 443 27.0% 270 26.7% 173 27.3% 0.805 
NRTI 1,503 91.4% 981 97.1% 522 82.3% <0.001 
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Pharmacokinetic Enhancer (ritonavir or 
cobicistat) 488 29.7% 263 26.0% 225 35.5% <0.001 
        
Single Tablet Regimen on Index Date or 
During Follow-up (N, %) 693 42.2% 505 50.0% 188 29.7% <0.001 
        
Mail Order ART Claim on Index Date or During 
Follow-up (N, %) 617 37.5% 388 38.4% 229 36.1% 0.349 
Abbreviations: ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PDC, proportion 
of days covered; PI, protease inhibitor; PLWH, people living with HIV; SD, standard deviation. 
*excludes Kaposi's sarcoma, cervical cancer, non-Hodgkin's lymphoma 
**This reflects medications that patients filled around the index date (±45 days). Patients may have been on other ART classes as part of their ART regimen, but if 
those medications were filled outside of this window, the medications would not be captured in this variable. 
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Chapter 4 Figure 2A-B. Unadjusted (A) and adjusted (B) odds ratios for non-adherence, defined 







Abbreviation: AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio; PDC, proportion of days covered. 
Models in 2B were adjusted for age, sex, region, urbanicity, types of ART classes filled ±45 days around the index 
date, presence of ≥1 claim for an ART single tablet regimen on the index date or during follow-up, presence of ≥1 
claim for ART filled via mail-order pharmacy on the index date or during follow-up, and pre-period ART adherence.
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Chapter 5: Dissertation Conclusions 
In this dissertation, I focused on elderly PLWH aged ≥65 years living in the US and insured 
through Medicare supplemental insurance plans. As PLWH live longer thanks to tolerable and 
effective medications, an understanding of these individuals from a clinical perspective is 
becoming increasingly important. As described in these analyses, elderly PLWH suffer from 
multimorbidity, typically at higher rates than similarly aged HIV-negative individuals, and require 
multiple comedications. Along with their healthcare providers, they must try to effectively 
manage multiple conditions at once, which can be challenging.  
In my first analysis, I found that elderly PLWH and elderly HIV-negative individual experience 
many of the same non-HIV conditions, such as hypertension and dyslipidemia, but the 
prevalence of these common age-related conditions is higher among PLWH. Both HIV-positive 
men and HIV-positive women had significantly higher numbers of non-HIV conditions compared 
to their HIV-negative counterparts of similar ages. Additionally, HIV-positive men had a 
significantly higher number of daily non-ART medications than HIV-negative men. The results 
are similar to previously published findings of “older” PLWH. However, my analysis adds to this 
body of literature in several ways. First, most research of older PLWH has evaluated individuals 
≥50 years old. My focus on PLWH age ≥65 is novel but logical as this is the definition of 
“elderly” used among the general US population and is linked to Medicare eligibility. Second, 
rather than limiting my analysis to a small number of non-HIV conditions, I evaluated 32 
conditions, including both physical and mental health conditions, based on previously published 
analyses, but also on conditions determined to be common in my sample of PLWH. Lastly, my 
initial analyses were stratified by sex. Many US-based analyses have used Veterans 
Administration data where >90% of the population is men and some have explicitly excluded 
women because of small numbers. 
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My second analysis built upon the previous work by investigating patterns of disease co-
occurrence rather than simply evaluating the number of non-HIV conditions. Using latent class 
analysis, I identified three similar classes among PLWH and HIV-negative individuals: a sickest 
class with high probabilities of several conditions, a class characterized by hypertension and 
dyslipidemia, and a healthiest class with low probabilities of non-HIV conditions. However, I 
observed that within the sickest class, certain non-HIV conditions, like kidney disease and 
anemia, were more common among PLWH. When I compared PLWH with demographically 
matched HIV-negative individuals, a greater proportion of PLWH were assigned to the sickest 
class. The contributions of this analysis include those mentioned above (analyzing PLWH age 
≥65 years and evaluating differences by sex). Additionally, I went beyond counting the number 
of conditions or analyzing the risk of individual conditions, by describing patterns of disease co-
occurrence. By using latent class analyses, I did not have to pre-specify the number of 
comorbidities in each class and could cluster individuals to identify subgroups of PLWH, rather 
than clusters of conditions. This methodology was used in only one other analysis of PLWH, but 
its popularity in the field of epidemiology is increasing. 
My final analysis explored the potential impact of the substantial comorbid disease and 
comedication burden facing elderly PLWH on adherence to ART. The majority of PLWH in this 
sample had filled enough ART to cover ≥80% of the 12-month follow-up period; however, less 
than half filled enough to cover ≥95%. I found a trend of increasing odds of non-adherence as 
the number of comorbidities increases and a trend of decreasing odds of non-adherence as the 
number of daily comedications increased in models including both variables. Other analyses in 
different populations have reported that specific comorbidities, like depression, as well as the 
number of comorbid conditions, negatively impact adherence. However, my finding regarding 
more comedications being associated with better adherence compared to fewer comedications 
was unexpected. It is possible that this relationship highlighted a trend among older PLWH of 
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filling many prescriptions, including ART. This analysis adds to the literature by focusing on 
PLWH age ≥65 years old, while many adherence studies analyze data from younger PLWH, 
and by analyzing several different variations of comorbid disease and comedication burden.  
These analyses also have limitations which should be noted. Many of these limitations are 
inherent to claims-based analyses, which are not generated for epidemiological research. 
Therefore, information that would have increased the accuracy of my findings, such as 
laboratory test results, HIV duration, over the counter medication use, self-report of ART 
adherence, written prescriptions, race, and socioeconomic status, were not available. My 
sample was drawn from a database of enrollees with Medicare supplemental insurance paid for 
by a former employer. They likely have higher socioeconomic status and more generous 
insurance benefits than other elderly PLWH who may have an even greater comorbidity and 
comedication burden and more barriers to ART adherence. Despite conducting sex-specific 
analyses, the number of HIV-positive women in this sample was still small and more studies are 
needed in this population. Finally, most PLWH, especially those who reach age 65, are in 
frequent contact with the healthcare system for their HIV infection. This may introduce screening 
bias when comparing comorbid disease and comedication burden among PLWH to HIV-
negative individuals, as PLWH will have more opportunity to be diagnosed with comorbidities, 
be diagnosed at younger ages, and have more medications prescribed. This limitation should be 
considered when interpreting not only the results of my analyses, but in all analyses comparing 
comorbidities among PLWH to those not living with HIV. 
In addition to more analyses focusing on elderly HIV-positive women, there are other areas for 
future research to address. Potential analyses in claims databases, such as the MarketScan 
Medicare Supplemental database, include an estimation of the cost impact of comorbid 
conditions among PLWH and an analysis of the impact of transitioning from commercial 
insurance to Medicare insurance on ART adherence and HIV care. Other future analyses could 
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be conducted to address some of the limitations of claims database. For example, these 
analyses could be replicated in other databases with different populations of elderly PLWH and 
with different available variables. In other databases, the impact of comorbidities and 
comedications on ART adherence could be assessed with other types of adherence measures, 
such as self-reported adherence. Unfilled prescriptions and adherence to comedications for 
other chronic conditions could also be evaluated among elderly PLWH. To date, most research 
of older PLWH has evaluated individuals age ≥50 years old; however, I suggest that future 
analyses focus on individuals age ≥65 years, or analyze them separately from those ages 50-
64, because the comorbid and comedication disease burden may differ between those age 
groups, and because in the US, age is tied to Medicare eligibility. Sex-specific analyses would 
also be valuable contributions to the literature in databases where there is a sufficient number of 
HIV-positive women to determine if differences in comorbid disease burden exist between HIV-
positive men and HIV-positive women exist. 
Another area of future research is the impact of neighborhood characteristics on comorbidities, 
comedications, and ART adherence among elderly PLWH. Neighborhood characteristics have 
been shown to affect HIV outcomes and disease outcomes for other conditions.1-5 For example, 
one analysis found that higher levels of neighborhood disorder were associated with non-
adherence to ART, mediated by homelessness and risky social situations.1 Another reported 
that higher neighborhood poverty was associated with lower CD4 counts and higher 
neighborhood unemployment was associated with lower likelihood of receiving ART.2 Poor 
quality built environment (which encompassed community aspects such as presence of trash 
and litter, poor building maintenance, and lack of opportunity for outdoor exercise) and racial 
segregation have also been associated with low CD4 counts among HIV-positive women.5 
In this dissertation, I attempted to analyze neighborhood-level characteristics based on US 
American Community Survey (ACS) data in all three analyses.6 In addition, neighborhood-level 
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characteristics based on the Area Health Resource File (AHRF) were included as part of the 
adherence analyses.7 Data from the 2011-2015 ACS 5-year estimates was merged to the 
enrollees selected from the claims database by 5-digit zip code of residence to add area-level 
sociodemographic and socioeconomic information (racial composition, education, and poverty 
levels). Data from the 2015-2016 release of the AHRF was merged to the enrollees selected 
from the claims database by county of residence to add area-level information on concentration 
of healthcare providers. County was used for these measures rather than 5-digit zip code 
because patients may travel outside of their zip code of residence for healthcare. Three 
variables were created based on the 5-digit zip code of the individual’s residence using the 
ACS: proportion of Black residents >50% (i.e., a segregated neighborhood),5 proportion of 
residents with a Bachelors degree or more is below the median for 5-digit zip codes in this 
dataset, and proportion of residents living in poverty is >25%5 (i.e., a neighborhood with 
concentrated poverty) and three variables were created based on the county of the individual’s 
residence using the AHRF: concentration of primary care providers is below the median for 
counties in this dataset, concentration of specialists is below the median, and concentration of 
pharmacists is below the median.  
Because the database encompassed the entire US, the number of individuals in any one zip 
code or county was very small. For the PLWH vs. HIV-negative analyses, the dataset included 
nearly 32,500 zip codes with an average of 62 people per zip code. Additionally, the LCA macro 
used to fit models for the second analysis does not have the capability of fitting multilevel 
models. For my third analysis, where the sample was limited to PLWH, in empty models, the 
pseudo intraclass correlation coefficients were very low (0.049 for county) which indicates a lack 
of similarity in terms of non-adherence among individuals within those groups or would not 
converge (zip code). Therefore, multilevel models could not be fit for any of the three analyses 
and neighborhood-level variables were included as individual-level variables in supplemental 
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models which are presented in Appendix 4. However, because of this, the neighborhood-level 
variables were not included in the final dissertation results. 
PLWH age ≥65 years in the US suffer from multiple comorbidities in addition to their HIV. 
Adequately managing multimorbidity and polypharmacy is a challenge for providers and for 
PLWH themselves. It is more complex than managing each condition individually, as the 
interrelatedness of the conditions along with drug-drug interactions must be considered, and it 
requires coordination among several types of healthcare providers, including primary care 
providers, specialist providers, and geriatricians. The results of these dissertation analyses 
include valuable information about the total comorbid disease and comedication burden of 
elderly PLWH, patterns of comorbid disease, and the potential impact of comorbidities on ART 
adherence. This understanding may aid healthcare practitioners, epidemiologists, and policy 
makers by providing evidence for the importance of primary prevention of comorbidities in this 
growing population and for the design and targeting of interventions aimed at reducing the 
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Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus. 
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with ≥2 medical claims with a diagnosis code for 
HIV between 1/1/2010 and 9/30/15 
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Appendix 1 Table 1. Demographic characteristics of PLWH and HIV-negative individuals, 
stratified by sex 
  PLWH: Men 
HIV-negative 
Individuals: Men PLWH: Women 
HIV-negative 
Individuals: Women 
  N=1,909 N=895,123 N=450 N=1,115,390 
 N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD 
         
Individual-Level Characteristics           
Age (Mean, SD) 71.26 4.91 75.36 7.19 72.12 6.20 76.53 7.82 
         
Age group (N, %)         
65-69 884 46.31% 237,894 26.58% 200 44.44% 260,794 23.38% 
70-74 628 32.90% 234,994 26.25% 142 31.56% 266,145 23.86% 
75-79 253 13.25% 172,087 19.22% 48 10.67% 211,801 18.99% 
80-84 92 4.82% 132,202 14.77% 30 6.67% 174,149 15.61% 
85+ 52 2.72% 117,946 13.18% 30 6.67% 202,501 18.16% 
 
  
      
Region (N, %) 
  
      
Northeast 503 26.35% 199,799 22.32% 150 33.33% 261,067 23.41% 
North Central 287 15.03% 286,399 32.00% 63 14.00% 354,504 31.78% 
West 543 28.44% 267,311 29.86% 177 39.33% 331,299 29.70% 
South 560 29.33% 136,947 15.30% 55 12.22% 163,814 14.69% 
Unknown 16 0.84% 4,667 0.52% 5 1.11% 4,706 0.42% 
         
Urbanicity (N, %)         
Urban 1,793 93.92% 746,056 83.35% 406 90.22% 945,535 84.77% 
Rural 104 5.45% 144,891 16.19% 39 8.67% 165,621 14.85% 
Unknown 12 0.63% 4,176 0.47% 5 1.11% 4,234 0.38% 
Abbreviations: HIV, human immunodeficiency syndrome; PLWH, people living with HIV. 
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Appendix 1 Table 2. Rank and prevalence of 3-digit diagnoses and therapeutic classes present 
in ≥15% of HIV-positive men or HIV-positive women 
  PLWH: Men PLWH: Women 
  Rank N % Rank N % 
Most Common 3-Digit ICD-9-CM Diagnosis Codes (N, %)             
401 Essential hypertension 1 870 45.6% 1 259 57.6% 
272 Disorders of lipid metabolism 2 669 35.0% 2 173 38.4% 
786 Symptoms involving respiratory system and other  
chest symptoms 3 584 30.6% 3 154 34.2% 
780 General symptoms 4 561 29.4% 4 150 33.3% 
250 Diabetes mellitus 5 495 25.9% 6 116 25.8% 
414 Other forms of chronic ischemic heart disease 6 422 22.1% 20/21 71 15.8% 
366 Cataract 7 421 22.1% 8 102 22.7% 
702 Other dermatoses 8 399 20.9% 41 24 5.3% 
729 Other disorders of soft tissues 9 383 20.1% 7 113 25.1% 
427 Cardiac dysrhythmias 10 357 18.7% 16 76 16.9% 
719 Other and unspecified disorder of joint 11 353 18.5% 5 126 28.0% 
V04 Need for prophylactic vaccination and inoculation  
against certain viral diseases 12 352 18.4% 13 80 17.8% 
600 Hyperplasia of prostate 13 319 16.7% N/A   
V58 Other and unspecified aftercare 14 316 16.6% 19 73 16.2% 
788 Symptoms involving urinary system 15 316 16.6% 31 50 11.1% 
724 Other and unspecified disorders of back 16 286 15.0% 12 84 18.7% 
787 Symptoms involving digestive system 17 285 14.9% 14 79 17.6% 
782 Symptoms involving skin and other integumentary 
tissue 19 261 13.7% 22/23 69 15.3% 
285 Other and unspecified anemias 20 249 13.0% 10/11 88 19.6% 
599 Other disorders of urethra and urinary tract 23/24 240 12.6% 18 74 16.4% 
365 Glaucoma 23/24 240 12.6% 22/23 69 15.3% 
276 Disorders of fluid, electrolyte, and acid-base balance 25/26 234 12.3% 10/11 88 19.6% 
789 Other symptoms involving abdomen and pelvis 29 223 11.7% 17 75 16.7% 
V72 Special investigations and examinations 33 205 10.7% 20/21 71 15.8% 
715 Osteoarthritis and allied disorders 34 202 10.6% 15 77 17.1% 
V76 Special screening for malignant neoplasms 38 174 9.1% 9 102 22.7% 
              
Most Common Medication Therapeutic Classes (N, %)             
Antihyperlipidemic Drugs: Not Elsewhere Classified 1 1,074 56.3% 1 235 52.2% 
Cardiac, Beta Blockers 2 620 32.5% 2 148 32.9% 
Analgesics/Antipyretics: Opiate Agonists 3 610 32.0% 3 135 30.0% 
Cardiac: ACE Inhibitors 4 573 30.0% 6 123 27.3% 
Unclassified Agents: Not Elsewhere Classified* 5 458 24.0% 33 23 5.1% 
Psychotherapeutic Agents: Antidepressants 6 451 23.6% 5 124 27.6% 
Cardiac: Calcium Channel 7 445 23.3% 4 131 29.1% 
Gastrointestinal Drugs Miscellaneous: Not Elsewhere  
Classified 8 441 23.1% 7 118 26.2% 
Quinolones: Not Elsewhere Classified 9 385 20.2% 11 83 18.4% 
Antivirals: Not Elsewhere Classified* 10 384 20.1% 26 53 11.8% 
Antibiotics: Penicillins 11 354 18.5% 12 83 18.4% 
Anxiolytics, Sedatives, and Hypnotics: Benzodiazepines 12 332 17.4% 14 81 18.0% 
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Analgesics/Antipyretics: Non-steroid/Anti-inflammatory 13 316 16.6% 8 92 20.4% 
Adrenals & Combinations: Not Elsewhere Classified* 14 313 16.4% 9 89 19.8% 
Antibiotics: Erythromycin & Macrolide 15 309 16.2% 13 83 18.4% 
Anti-inflammatory Skin/Mucous Membrane Agents &  
Combinations: Miscellaneous 16 304 15.9% 19 65 14.4% 
Cardiac Drugs: Not Elsewhere Classified 17 298 15.6% 10 89 19.8% 
Anti-inflammatory Agents Eye, Ear, Nose, and Throat: Not  
Elsewhere Classified 18 296 15.5% 18 68 15.1% 
Sulfonamides & Combinations: Not Elsewhere Classified 19 274 14.4% 15 76 16.9% 
Anticonvulsants, Miscellaneous 23 252 13.2% 16 75 16.7% 
Sympathomimetic Agents: Not Elsewhere Classified 24 239 12.5% 17 73 16.2% 
Abbreviations: HIV, human immunodeficiency virus; ICD-9-CM, International Classification of Diseases, Ninth Edition, 
Clinical Modification; PLWH, people living with HIV. 
*Unclassified agents includes medications for benign prostate hyperplasia. Antivirals includes medications for 
hepatitis, influenza, cytomegalovirus, and herpes. Adrenals includes corticosteroids. 
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Appendix 1 Figure 2A-B. Standardized prevalence of non-HIV conditions and AIDS-defining cancers per 100 people with 95% 





Abbreviations: HIV, human immunodeficiency virus; PLWH, people living with HIV; PR, prevalence ratio. 
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Appendix 1 Table 3. Number of non-HIV conditions of interest and number of daily non-ART medications 
  PLWH 
HIV-negative 



















             
Number of non-HIV 
conditions of 
interest (Mean, SD) 
4.61 3.06 3.94 2.79 4.59 3.09 4.68 2.96 4.04 2.85 3.85 2.74 
   Median, IQR 4 2-6 4 2-6 4 2-6 4 2-6 4 2-6 4 2-5 
             
≥2 non-HIV 
conditions of 
interest (N, %) 
2,036 86.31% 1,598,853 79.52% 1,640 85.91% 396 88.00% 715,424 79.92% 883,429 79.20% 
             




3.79 3.09 3.41 2.76 3.86 3.13 3.49 2.90 3.42 2.79 3.40 2.74 
Median, IQR 3.16 1.38-5.48 2.95 1.21-5.01 3.24 1.42-5.53 2.72 1.29-5.08 2.96 1.17-5.05 2.94 1.23-4.98 
 
            
≥5 non-ART 
medications per 
day (N, %) 
680 28.83% 504,692 25.10% 567 29.70% 113 25.11% 227,760 25.44% 276,932 24.83% 
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; PLWH, people living with HIV; SD, standard deviation. 
Note. p-values comparing means and proportions among PLWH with HIV-negative individuals were all <0.001. p-values comparing mean number 
of non-HIV conditions between men and women with HIV was 0.575, comparing proportions of individuals with ≥2 non-HIV conditions was 0.246, 






Appendix 1 Table 4A. Complete modeling results for number of non-HIV conditions 
 Adjusted Sensitivity Analysis1 
 Men Women Men Women 
 Ratio for Number of 




Ratio for Number of 




Ratio for Number of 




Ratio for Number of 
Non-HIV Conditions 
 (95% CI) 
p-
value 
         
PLWH vs. HIV-
negative2 
1.272 (1.233-1.312) <0.001 1.326 (1.245-1.413) <0.001 1.243 (1.199-1.288) <0.001 1.221 (1.134-1.315) <0.001 
         
Age, years         
70-74 vs. 65-69 1.205 (1.200-1.210) <0.001 1.179 (1.174-1.183) <0.001 1.250 (1.244-1.256) <0.001 1.195 (1.189-1.201) <0.001 
75-59 vs. 65-69 1.387 (1.381-1.393) <0.001 1.332 (1.326-1.338) <0.001 1.479 (1.471-1.487) <0.001 1.359 (1.352-1.366) <0.001 
80-84 vs. 65-69 1.515 (1.508-1.523) <0.001 1.422 (1.416-1.429) <0.001 1.646 (1.637-1.655) <0.001 1.457 (1.449-1.464) <0.001 
85+ vs 65-69 1.591 (1.583-1.599) <0.001 1.474 (1.468-1.480) <0.001 1.753 (1.744-1.763) <0.001 1.532 (1.525-1.540) <0.001 
         
Region         
North Central 
vs. Northeast 
0.950 (0.946-0.954) <0.001 0.977 (0.973-0.980) <0.001 0.930 (0.926-0.934) <0.001 0.962 (0.958-0.966) <0.001 
West vs. 
Northeast 
0.917 (0.914-0.921) <0.001 0.926 (0.922-0.929) <0.001 0.895 (0.891-0.899) <0.001 0.907 (0.903-0.911) <0.001 
South vs. 
Northeast 
0.828 (0.824-0.832) <0.001 0.860 (0.856-0.864) <0.001 0.804 (0.799-0.808) <0.001 0.842 (0.838-0.847) <0.001 
Unknown vs. 
Northeast 
0.533 (0.495-0.573) <0.001 0.558 (0.517-0.602) <0.001 0.521 (0.478-0.568) <0.001 0.552 (0.505-0.605) <0.001 
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Urbanicity         
Rural vs. Urban 0.964 (0.960-0.968) <0.001 0.957 (0.954-0.961) <0.001 0.962 (0.958-0.967) <0.001 0.958 (0.953-0.962) <0.001 
Unknown vs. 
Urban 
1.514 (1.403-1.634) <0.001 1.407 (1.301-1.523) <0.001 1.480 (1.352-1.621) <0.001 1.356 (1.234-1.490) <0.001 
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; PLWH, people living with HIV. 
1Doesn’t include hypertension, osteoporosis, ischemic heart disease, dyslipidemia, liver disease, depression, kidney disease, and anemia. 
2Ns for models were: men with HIV=1,909; HIV-negative men=895,123; women with HIV=450; and HIV-negative women=1,115,390. 
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Appendix 1 Table 4B. Complete modeling results for having no non-ART medications 
 Adjusted 
 Men Women 
 Odds Ratio for Having No Non-ART Medications 
 (95% CI) 
p-value Odds Ratio for Having No Non-ART Medications 
 (95% CI) 
p-value 
     
PLWH vs. HIV-negative1 0.523 (0.427-0.642) <0.001 0.840 (0.586-1.203) 0.341 
     
Age, years     
70-74 vs. 65-69 0.777 (0.762-0.792) <0.001 0.857 (0.841-0.874) <0.001 
75-59 vs. 65-69 0.645 (0.630-0.659) <0.001 0.762 (0.746-0.779) <0.001 
80-84 vs. 65-69 0.636 (0.620-0.652) <0.001 0.787 (0.770-0.805) <0.001 
85+ vs 65-69 0.750 (0.732-0.769) <0.001 0.954 (0.935-0.974) <0.001 
     
Region     
North Central vs. Northeast 1.160 (1.136-1.185) <0.001 1.197 (1.175-1.220) <0.001 
West vs. Northeast 1.050 (1.028-1.073) <0.001 1.071 (1.051-1.092) <0.001 
South vs. Northeast 1.232 (1.202-1.262) <0.001 1.142 (1.117-1.169) <0.001 
Unknown vs. Northeast 5.428 (4.479-6.577) <0.001 4.973 (4.070-6.078) <0.001 
     
Urbanicity     
Rural vs. Urban 0.916 (0.942-0.982) <0.001 0.979 (0.960-0.998) 0.028 
Unknown vs. Urban 0.438 (0.356-0.538) <0.001 0.572 (0.462-0.709) <0.001 
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Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; PLWH, people living with HIV. 
1Ns for models were: men with HIV=1,909; HIV-negative men=895,123; women with HIV=450; and HIV-negative women=1,115,390. 
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Appendix 1 Table 4C. Complete modeling results for number of daily non-ART medications 
among people with non-ART medication use 
 Adjusted 
 Men Women 
 Ratio for Number of Non-ART 
Medications per Day (95% CI) 
p-
value 
Ratio for Number of Non-ART 
Medications per Day (95% CI) 
p-
value 
     
PLWH vs. HIV-
negative1 
1.178 (1.133-1.226) <0.001 1.086 (1.003-1.176) 0.043 
     
Age, years     
70-74 vs. 65-69 1.133 (1.128-1.139) <0.001 1.118 (1.113-1.123) <0.001 
75-59 vs. 65-69 1.242 (1.235-1.249) <0.001 1.224 (1.218-1.230) <0.001 
80-84 vs. 65-69 1.305 (1.297-1.313) <0.001 1.302 (1.295-1.309) <0.001 
85+ vs 65-69 1.318 (1.309-1.326) <0.001 1.330 (1.323-1.336) <0.001 
     
Region     
North Central vs. 
Northeast 
0.993 (0.988-0.998) 0.005 1.048 (1.044-1.053) <0.001 
West vs. 
Northeast 
1.045 (1.040-1.050) <0.001 1.116 (1.111-1.121) <0.001 
South vs. 
Northeast 
0.941 (0.935-0.947) <0.001 0.996 (0.990-1.001) 0.107 
Unknown vs. 
Northeast 
0.835 (0.763-0.914) <0.001 0.931 (0.852-1.017) 0.114 
     
Urbanicity     
Rural vs. Urban 0.996 (0.991-1.001) 0.086 1.019 (1.015-1.024) <0.001 
Unknown vs. 
Urban 
1.127 (1.025-1.238) 0.013 1.051 (0.958-1.154) 0.293 
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; PLWH, 
people living with HIV. 





Appendix 2: Appendix to Chapter 3
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Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus. 
 
Individuals with Medicare Supplemental insurance 
with ≥2 medical claims with a diagnosis code for 
HIV between 1/1/2010 and 9/30/15 
OR 
≥1 medical claim with a diagnosis code for HIV 
AND ≥1 outpatient pharmacy claim for ART 
between 1/1/2010 and 9/30/15 
 
Date of most recent claim with HIV diagnosis = 
index diagnosis date 
 
N=6,310 (100%) 
People Living with HIV 
 









Individuals with Medicare Supplemental insurance 
with no medical claims with a diagnosis code for 
HIV AND no claims for ART between 1/1/2010 and 
9/30/15 
 
















Appendix 2 Table 1. Demographic characteristics of PLWH and HIV-negative individuals 









  N=2,359 N=2,010,513 N=23,590 
 N/Mean %/SD N/Mean %/SD N/Mean %/SD 
        
Age (Mean, SD) 71.42 5.19 76.01 7.56 <0.001 71.42 5.19 
         
     
Age group (N, %)              
65-69 1,084 45.95% 498,688 24.80% <0.001 10,840 45.95% 
70-74 770 32.64% 501,139 24.93%  7,700 32.64% 
75-79 301 12.76% 383,888 19.09%  3,010 12.76% 
80-84 122 5.17% 306,351 15.24%  1,220 5.17% 
85+ 82 3.48% 320,447 15.94%  820 3.48% 
         
     
Men (N, %) 1,909 80.92% 895,123 44.52% <0.001 19,090 80.92% 
          
Region (N, %)              
Northeast 653 27.68% 460,866 22.92% <0.001 6,530 27.68% 
North Central 350 14.84% 640,903 31.88%  3,500 14.84% 
West 720 30.52% 598,610 29.77%  7,200 30.52% 
South 615 26.07% 300,761 14.96%  6,150 26.07% 
Unknown 21 0.89% 9,373 0.47%  210 0.89% 
         
     
Urbanicity (N, %)              
Urban 2,199 93.22% 1,691,591 84.14% <0.001 21,990 93.22% 
Rural 143 6.06% 310,512 15.44%  1,430 6.06% 
Unknown 17 0.72% 8,410 0.42%  170 0.72% 




Appendix 2 Table 2. Prevalence and number of non-HIV conditions among PLWH and HIV-negative individuals 













 N=2,359 N=2,010,513 N=23,590 
 N/Mean/Median %/SD/IQR N/Mean/Median %/SD/IQR N/Mean/Median %/SD/IQR 
         
Number of non-HIV 
conditions (Mean, SD) 
4.61 3.06 3.94 2.79 <0.001 3.57 2.65 <0.001 
    Median, IQR 4 2-6 4 2-6  3 2-5  
         
Diagnosis of Non-HIV 




Hypertension 1,472 62.40% 1,224,564 60.91% 0.138 13,501 57.23% <0.001 
Dyslipidemia 1,293 54.81% 942,840 46.90% <0.001 11,402 48.33% <0.001 
Diabetes 685 29.04% 481,488 23.95% <0.001 5,838 24.75% <0.001 
Ischemic heart disease1 591 25.05% 422,224 21.00% <0.001 5,021 21.28% <0.001 
Cataract 573 24.29% 505,307 25.13% 0.345 5,740 24.33% 0.964 
Anemia 501 21.24% 235,207 11.70% <0.001 2,088 8.85% <0.001 
Cardiac dysrhythmia 465 19.71% 363,473 18.08% 0.039 3,515 14.90% <0.001 
Kidney disease 453 19.20% 162,460 8.08% <0.001 1,544 6.55% <0.001 
Chronic pulmonary disease 442 18.74% 309,076 15.37% <0.001 3,148 13.34% <0.001 
Non-AIDS-defining cancer2 387 16.41% 244,026 12.14% <0.001 2,951 12.51% <0.001 
Depression 356 15.09% 163,615 8.14% <0.001 1,589 6.74% <0.001 
Benign prostate hyperplasia  337 14.29% 159,057 7.91% <0.001 3,099 13.14% 0.117 
Glaucoma 322 13.65% 286,963 14.27% 0.387 2,931 12.42% 0.087 
Osteoarthritis 304 12.89% 386,352 19.22% <0.001 3,619 15.34% 0.002 
Cerebrovascular disease 283 12.00% 231,834 11.53% 0.479 2,233 9.47% <0.001 
Peptic ulcer 
disease/esophageal reflux 




Retinal disorders3 270 11.45% 282,708 14.06% <0.001 2,419 10.25% 0.070 
Heart valve disorders (non-
rheumatic) 




Congestive heart failure 243 10.30% 147,870 7.35% <0.001 1,143 4.85% <0.001 
Peripheral vascular disease 200 8.48% 138,746 6.90% 0.003 1,408 5.97% <0.001 
Unspecified acquired 
hypothyroidism 




Substance abuse 178 7.55% 66,498 3.31% <0.001 990 4.20% <0.001 
Anxiety 171 7.25% 116,621 5.80% 0.003 1,019 4.32% <0.001 
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Hepatitis C 133 5.64% 3,976 0.20% <0.001 73 0.31% <0.001 
Tobacco use disorder 127 5.38% 52,150 2.59% <0.001 761 3.23% <0.001 
Dementia 107 4.54% 107,362 5.34% 0.082 646 2.74% <0.001 
Osteoporosis 98 4.15% 115,896 5.76% 0.001 601 2.55% <0.001 
Liver disease 61 2.59% 9,223 0.46% <0.001 135 0.57% <0.001 
Hemiplegia/paraplegia 31 1.31% 10,075 0.50% <0.001 90 0.38% <0.001 
Bipolar disorder 27 1.14% 10,798 0.54% <0.001 136 0.58% <0.001 
Rheumatologic disease 25 1.06% 50,900 2.53% <0.001 409 1.73% 0.001 
Schizophrenia 8 0.34% 3,163 0.16% <0.001 41 0.17% 0.015 
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; PLWH, people living with HIV; SD, standard deviation. 
















1 -13979.47 2846.29 2868.29 2931.71 2942.71 2896.76 1.00 2036 100% 
2 -13434.30 1755.95 1801.95 1934.57 1957.57 1861.49 0.62 2024 100% 
3 -13350.10 1587.56 1657.56 1859.37 1894.37 1748.17 0.55 2012 74.8% 
4 -13289.02 1465.39 1559.39 1830.39 1877.39 1681.06 0.53 2000 99.2% 
5 -13257.94 1403.23 1521.23 1861.42 1920.42 1673.97 0.54 1988 65.8% 
6 -13240.59 1368.53 1510.53 1919.91 1990.91 1694.33 0.58 1976 21.2% 
7 -13228.92 1345.19 1511.19 1989.77 2072.77 1726.06 0.64 1964 1.2% 












1 -10421950.37 1099087.43 1099109.43 1099247.08 1099258.08 1099212.12 1.00 2036 100% 
2 -9987758.19 230703.08 230749.08 231036.90 231059.90 230963.80 0.57 2024 100% 
3 -9931132.82 117450.34 117520.34 117958.33 117993.33 117847.10 0.56 2012 100% 
4 -9912658.30 80503.30 80597.30 81185.45 81232.45 81036.08 0.70 2000 11.0% 
5 -9897799.59 50785.88 50903.88 51642.20 51701.20 51454.69 0.48 1988 19.6% 
6 -9890377.26 35941.21 36083.21 36971.69 37042.69 36746.05 0.45 1976 1.8% 
7 -9884727.36 24641.42 24807.42 25846.08 25929.08 25582.3 0.51 1964 34.8% 












1 -117613.52 14749.88 14771.88 14860.63 14871.63 14825.67 1.00 2036 100% 
2 -112303.77 4130.37 4176.37 4361.95 4384.95 4288.86 0.59 2024 100% 
3 -111660.67 2844.18 2914.18 3196.58 3231.58 3085.35 0.61 2012 100% 
4 -111475.65 2474.14 2568.14 2947.37 2994.37 2798.00 0.47 2000 69.6% 
5 -111306.17 2135.17 2253.17 2729.21 2788.21 2541.71 0.48 1988 98.6% 
6 -111234.64 1992.12 2134.12 2706.98 2777.98 2481.35 0.49 1976 71.0% 
7 -111182.37 1887.58 2053.58 2723.27 2806.27 2459.50 0.56 1964 15.4% 
8 -111139.20 1801.23 1991.23 2757.75 2852.75 2455.84 0.64 1952 4.20% 
Abbreviations: AIC, Akaike information criterion; ABIC, adjusted Bayesian information criterion; BIC, Bayesian 
information criterion; CAIC, consistent Akaike information criterion; DF, degrees of freedom; HIV, human 





Appendix 2 Table 4. Unadjusted item-response probabilities for classes of PLWH and HIV-negative individuals using a 4-class 
solution 
 PLWH All HIV-Negative Individuals Matched HIV-Negative Individuals 

























Ischemic heart disease 0.72 0.34 0.21 0.02 0.57 1.00 0.00 0.04 0.63 0.29 0.14 0.01 
Cardiac dysrhythmia 0.61 0.14 0.32 0.03 0.51 0.34 0.15 0.05 0.49 0.14 0.15 0.01 
Hypertension 0.98 0.84 0.58 0.32 0.93 0.83 0.80 0.16 0.94 0.88 0.48 0.13 
Dyslipidemia 0.74 0.81 0.34 0.35 0.67 0.71 0.60 0.13 0.76 0.78 0.38 0.10 
Chronic pulmonary disease 0.37 0.17 0.30 0.07 0.37 0.21 0.15 0.07 0.34 0.11 0.16 0.03 
Diabetes 0.72 0.38 0.13 0.15 0.49 0.34 0.28 0.07 0.51 0.38 0.17 0.06 
Kidney disease 0.63 0.19 0.19 0.04 0.44 0.06 0.07 0.00 0.33 0.05 0.04 0.00 
Non-AIDS-defining cancer 0.24 0.11 0.35 0.09 0.24 0.13 0.13 0.07 0.25 0.10 0.17 0.05 
Depression 0.26 0.15 0.23 0.07 0.19 0.08 0.09 0.04 0.15 0.05 0.09 0.02 
Anemia 0.76 0.09 0.41 0.02 0.62 0.07 0.09 0.03 0.43 0.03 0.10 0.00 
Cataracts 0.30 0.28 0.20 0.22 0.24 0.28 0.30 0.17 0.29 0.29 0.27 0.13 
             
Estimated class prevalence 12.2% 33.4% 20.1% 34.4% 9.5% 14.2% 43.5% 32.8% 11.2% 32.4% 31.0% 25.4% 
Proportion of cohort assigned to 
class* 
11.3% 36.5% 16.4% 35.7% 7.4% 15.2% 48.0% 29.4% 8.9% 35.9% 28.1% 27.1% 
Mean posterior probability 0.82 0.70 0.69 0.77 0.77 0.85 0.81 0.85 0.76 0.68 0.60 0.74 
Abbreviations: DYS, dyslipidemia; HIV, human immunodeficiency virus; HTN, hypertension; PLWH, people living with HIV. 
Item-response probabilities of approximately 0.50 or more are bolded for interpretation 
*Assignment is based on maximum posterior probability 
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Appendix 2 Table 5. Unadjusted item-response probabilities for classes of PLWH and HIV-negative individuals using a 3-class 
solution 
 PLWH All HIV-Negative Individuals Matched HIV-Negative Individuals 
 N=2,359 N=2,010,513 N=23,590 
 Sickest HTN/ 
DYS 
Healthiest Sickest HTN/ 
DYS 
Healthiest Sickest HTN/ 
DYS 
Healthiest 
Ischemic heart disease 0.60 0.35 0.05 0.60 0.23 0.04 0.63 0.27 0.03 
Cardiac dysrhythmia 0.56 0.14 0.09 0.54 0.17 0.06 0.51 0.16 0.04 
Hypertension 0.90 0.83 0.38 0.92 0.82 0.22 0.91 0.79 0.18 
Dyslipidemia 0.64 0.83 0.33 0.67 0.66 0.15 0.73 0.68 0.14 
Chronic pulmonary disease 0.37 0.18 0.12 0.36 0.15 0.08 0.36 0.14 0.07 
Diabetes 0.54 0.37 0.14 0.45 0.30 0.07 0.51 0.33 0.07 
Kidney disease 0.51 0.18 0.07 0.34 0.06 0.01 0.35 0.06 0.00 
Non-AIDS-defining cancer 0.28 0.11 0.15 0.22 0.13 0.08 0.26 0.13 0.09 
Depression 0.26 0.15 0.11 0.17 0.09 0.04 0.16 0.07 0.04 
Anemia 0.70 0.07 0.11 0.47 0.08 0.03 0.45 0.07 0.02 
Cataracts 0.26 0.28 0.21 0.24 0.31 0.18 0.28 0.29 0.17 
          
Estimated class prevalence 19.8% 31.0% 49.2% 13.8% 48.9% 37.3% 10.0% 52.1% 37.9% 
Proportion of cohort assigned to class* 18.4% 32.2% 49.4% 10.9% 50.8% 38.3% 7.1% 54.3% 38.6% 
Mean posterior probability 0.83 0.70 0.84 0.76 0.78 0.82 0.77 0.81 0.83 
Abbreviations: DYS, dyslipidemia; HIV, human immunodeficiency virus; HTN, hypertension; PLWH, people living with HIV. 
Item-response probabilities of approximately 0.50 or more are bolded for interpretation. 
*Assignment is based on maximum posterior probability 
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Appendix 2 Table 6. Combined PLWH and HIV-negative for 3-class model: measurement non-invariance vs. invariance  
  
Log-








PLWH and All 
HIV-Negative 
Individuals           
Invariance in item-
response 
probabilities -9944717.99 119510.03 119584.03 120047.09 120084.09 119929.5 0.56 4058 100% 
ΔG2 = 
472.22 
Δdf = 33 
p-value 









Individuals           
Invariance in item-
response 
probabilities -125229.6 4869.39 4943.39 5245.45 5282.45 5127.87 0.61 4058 100% 
ΔG2 = 
437.64 
Δdf = 33 
p-value 





probabilities -125010.78 4431.75 4571.75 5143.22 5213.22 4920.76 0.60 4025 75% 
Abbreviations: AIC, Akaike information criterion; ABIC, adjusted Bayesian information criterion; BIC, Bayesian information criterion; CAIC, consistent Akaike 
information criterion; DF, degrees of freedom; HIV, human immunodeficiency virus; PLWH, people living with HIV.  
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Appendix 2 Table 7. Unadjusted item-response probabilities for 3-class multigroup latent class 
analysis with measurement non-invariance 
 PLWH All HIV-Negative 
Individuals 
Absolute Difference in 
Probability 
PLWH minus HIV-Negative  N=2,359 N=2,010,513 
 Sickest HTN/ 
DYS 
Healthiest Sickest HTN/ 
DYS 




disease 0.60 0.35 0.05 0.60 0.23 0.04 0.00 0.11 0.01 
Cardiac 
dysrhythmia 0.56 0.14 0.09 0.54 0.17 0.06 0.02 -0.03 0.03 
Hypertension 0.90 0.83 0.38 0.92 0.82 0.22 -0.02 0.01 0.16 
Dyslipidemia 0.64 0.83 0.33 0.67 0.66 0.15 -0.03 0.17 0.19 
Chronic 
pulmonary 
disease 0.37 0.18 0.12 0.36 0.15 0.08 0.01 0.03 0.04 
Diabetes 0.54 0.37 0.14 0.45 0.30 0.07 0.09 0.07 0.06 
Kidney disease 0.51 0.18 0.07 0.34 0.06 0.01 0.17 0.12 0.06 
Non-AIDS-
defining cancer 0.28 0.11 0.15 0.22 0.13 0.08 0.06 -0.01 0.07 
Depression 0.26 0.15 0.11 0.17 0.09 0.04 0.09 0.06 0.06 
Anemia 0.70 0.07 0.11 0.47 0.08 0.03 0.23 -0.01 0.07 
Cataracts 0.26 0.28 0.21 0.24 0.31 0.18 0.03 -0.03 0.03 
 PLWH Matched HIV-Negative 
Individuals 
Absolute Difference in 
Probability 
PLWH minus HIV-Negative  N=2,359 N=23,590 
 Sickest HTN/ 
DYS 
Healthiest Sickest HTN/ 
DYS 




disease 0.60 0.35 0.05 0.63 0.27 0.03 -0.03 0.08 0.02 
Cardiac 
dysrhythmia 0.56 0.14 0.09 0.51 0.16 0.04 0.05 -0.02 0.05 
Hypertension 0.90 0.83 0.38 0.91 0.79 0.18 -0.01 0.04 0.20 
Dyslipidemia 0.64 0.83 0.33 0.73 0.68 0.14 -0.09 0.15 0.19 
Chronic 
pulmonary 
disease 0.37 0.18 0.12 0.36 0.14 0.07 0.01 0.04 0.05 
Diabetes 0.54 0.37 0.14 0.51 0.33 0.07 0.03 0.04 0.07 
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Kidney disease 0.51 0.18 0.07 0.35 0.06 0.00 0.16 0.13 0.07 
Non-AIDS-
defining cancer 0.28 0.11 0.15 0.26 0.13 0.09 0.02 -0.02 0.06 
Depression 0.26 0.15 0.11 0.16 0.07 0.04 0.11 0.08 0.07 
Anemia 0.70 0.07 0.11 0.45 0.07 0.02 0.25 0.00 0.08 
Cataracts 0.26 0.28 0.21 0.28 0.29 0.17 -0.02 -0.02 0.05 
Abbreviations: DYS, dyslipidemia; HIV, human immunodeficiency virus; HTN, hypertension; PLWH, people living with 
HIV. 






In addition to identifying classes of individuals, I also explored clusters of non-HIV conditions to 
describe comorbidity co-occurrence. To date, clusters of comorbid conditions among PLWH 
have not been well-described. One analysis classified comorbidities into three very broad 
clusters: mental disorders, medical disorders, and alcohol-related complications1 and a second 
analysis identified a metabolic condition cluster, a behavioral condition cluster, and a substance 
use cluster .2 In both analyses, the majority of the PLWH analyzed were in their forties, which is 
younger than patients traditionally considered elderly in the US. I aimed to describe clusters of 
non-HIV conditions among PLWH and HIV-negative individuals aged 65 and older insured 
through Medicare, stratified by sex. 
Cluster analysis was used to categorize the binary flags for each of the non-HIV health 
conditions based on the similarities between the conditions.3 The similarities between the 
conditions were calculated using Jaccard’s coefficient which weights positive matches (when 
both conditions are present) but gives no weights to negative matches.3 Agglomerative 
hierarchical clustering with average linkage method was used to cluster the non-HIV health 
conditions based on these similarities. The number of appropriate clusters was determined by 
the pseudo F statistic, pseudo t statistics, and clinical and epidemiological knowledge. Clusters 
are displayed with dendograms. Cluster analysis was done for all PLWH and HIV-negative 
individuals, and then for men and women, separately. The non-HIV conditions evaluated were 
limited to those that were present in ≥15% of the PLWH cohort to prevent small clusters and 
classes and to allow for comparison between the PLWH and HIV-negative cohorts. 
There were 11 conditions that were present in ≥15% of PLWH, 11 conditions that were present 
in ≥15% of HIV-positive men, and 13 conditions that were present in ≥15% of HIV-positive 
women. The optimal number of clusters differed for PLWH, HIV-negative individuals, and 
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matched HIV-negative individuals, as well as in the sex-stratified analysis (Appendix 2 Figure 
8A-I). Among PLWH, there were seven clusters identified (Appendix 2 Figure 8A). The largest 
cluster was hypertension, dyslipidemia, and diabetes. These conditions were also the most 
prevalent overall among PLWH (hypertension=62.40%, dyslipidemia=54.81%, and 
diabetes=29.04%). Ischemic heart disease and cardiac dysrhythmia were clustered together, as 
were kidney disease and anemia. The remaining four clusters contained only one condition 
each.  Among HIV-negative individuals, there were four clusters, including one large cluster that 
contained seven of the 11 conditions (Appendix 2 Figure 8B), and among matched HIV-negative 
individuals, there were eight clusters identified (Appendix 2 Figure 8C). In all three analyses, 
hypertension, dyslipidemia, and diabetes were in the same cluster.  
Because the majority of PLWH in this sample were men, the clusters among HIV-positive men 
(Appendix 2 Figure 8D) and the matched sample of HIV-positive men (Appendix 2 Figure 8F) 
were similar to the overall PWLH and matched HIV-negative clusters. Among HIV-negative 
men, there were eight clusters identified with the largest cluster including hypertension, 
dyslipidemia, diabetes, and ischemic heart disease (Appendix 2 Figure 8E). Three of the 
clusters present in PLWH were also present in HIV-positive women (Appendix 2 Figure 8G). 
Additionally, chronic pulmonary disease and depression clustered together and cataract and 
glaucoma clustered together. In all HIV-negative women (Appendix 2 Figure 8H) and matched 
HIV-negative women (Appendix 2 Figure 8I), a large cluster was present which included 
hypertension, dyslipidemia, diabetes, cataract, and osteoarthritis. Among matched HIV-negative 





1. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and 
treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. 
AIDS. 2005;19(suppl 3):S99-S105. 
2. Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity patterns in HIV-infected patients: 
the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 
2012;61(5):600-605. 
3. Steinman MA, Lee SJ, Boscardin WJ, et al. Patterns of multimorbidity in elderly 
veterans. J Am Geriatr Soc. 2012;60(10):1872-1880. 
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Appendix 2 Figure 8A-I. Dendograms of non-HIV condition clusters for PLWH, HIV-negative 























Other Characteristics Associated with ART Adherence 
In the models using 80% as the cut-off for adherence, PLWH ages 70-74 or 75-79 compared to 
those 65-69, and PLWH who were not adherent during the pre-period compared to those who 
were adherent during the pre-period had higher odds of being non-adherent. Using an NNRTI, 
an integrase inhibitor, or NRTI, filling a claim for a single tablet regimen, and filling an ART claim 
via mail-order pharmacy were associated with better ART adherence (Appendix 3 Table 4). 
In the models using 95% as the cut-off, PLWH ages 70-74 vs. 65-69, PLWH living in the North 
Central vs. Northeast, and PLWH who were not adherent during the pre-period vs. those who 
were adherent during the pre-period had lower odds of being adherent. Use of NNRTIs, PIs, 
integrase inhibitors, or NRTIs, and filling a single tablet regimen were associated with higher 
odds of being adherent (Appendix 3 Table 5). 
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Appendix 3 Table 1. LCA results 















Hypertension 0.32 0.87 0.57 0.15 0.74 0.53 0.98 
Dyslipidemia 0.34 0.75 0.59 0.18 0.64 0.57 0.81 
Diabetes 0.12 0.45 0.13 0.07 0.28 0.22 0.68 
Cataract 0.18 0.27 1.00 0.12 0.03 0.60 0.42 
Ischemic heart disease 0.07 0.38 0.05 0.02 0.27 0.14 0.49 
Renal disease 0.05 0.30 0.06 0.03 0.17 0.10 0.49 
Glaucoma 0.08 0.17 1.00 0.07 0.05 0.32 0.27 
Chronic pulmonary 





Appendix 3 Table 2. Demographic characteristics of elderly PLWH, stratified by ART adherence using 95% cut-off 
  
PATIENTS ADHERENT TO 
ART (PDC≥95%) 
PATIENTS NOT ADHERENT 
TO ART (PDC<95%) 
p-value 
  N= 673 (40.9%) N= 971 (59.1%) 
 N/Mean %/SD N/Mean %/SD 
      
Age (Mean, SD) 70.3 4.1 71.1 4.7 <0.001 
      
Age group (N, %)      
65-69 368 54.7% 439 45.2% 0.001 
70-74 211 31.4% 339 34.9%  
75-79 68 10.1% 126 13.0%  
80-84 19 2.8% 48 4.9%  
85+ 7 1.0% 19 2.0%  
      
Sex (N, %)      
Male 569 84.5% 786 80.9% 0.059 
Female 104 15.5% 185 19.1%  
      
Region (N, %)      
Northeast 197 29.3% 266 27.4% 0.009 
North Central 84 12.5% 161 16.6%  
West 189 28.1% 311 32.0%  
South 197 29.3% 229 23.6%  
Unknown 6 0.9% 4 0.4%  
      
Urbanicity (N, %)      
Urban 635 94.4% 910 93.7% 0.502 
Rural 34 5.1% 58 6.0%  
Unknown 4 0.6% 3 0.3%  
      
Index Year (N, %)      
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2010 23 3.4% 41 4.2% <0.001 
2011 62 9.2% 79 8.1%  
2012 120 17.8% 176 18.1%  
2013 116 17.2% 187 19.3%  
2014 29 4.3% 107 11.0%  
2015 323 48.0% 381 39.2%  
 
Abbreviations: PDC, proportion of days covered; PLWH, people living with HIV; SD, standard deviation.
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Appendix 3 Table 3. Clinical characteristics of elderly PLWH, stratified by ART adherence using a 95% cutoff 
  
PATIENTS ADHERENT TO 
ART (PDC≥95%) 
PATIENTS NOT ADHERENT 
TO ART (PDC<95%) 
p-value 
  N= 673 (40.9%) N= 971 (59.1%) 
 N/Mean %/SD N/Mean %/SD 
      
Comorbidity (N, %)      
Number of comorbidities (Mean, SD) 3.7 2.5 4.3 2.9 <0.001 
Median, interquartile range 3 2-5 4 2-6   
           
Number of comorbidities: ≤2 250 37.1% 303 31.2% 0.001 
Number of comorbidities: 3-4 209 31.1% 270 27.8%   
Number of comorbidities: 5-6 126 18.7% 213 21.9%   
Number of comorbidities: ≥7 88 13.1% 185 19.1%   
      
Medications, including ART       
Number of daily medications** (Mean, SD) 5.8 3.5 5.6 3.3 0.159 
Median, interquartile range 5.1 3.3-7.6 5.0 3.0-7.6  
Comedications, not including ART       
Number of daily non-ART medications** (Mean, SD) 4.0 3.1 3.9 3.0 0.388 
Median, interquartile range 3.5 1.7-5.6 3.3 1.6-5.6  
      
Number of daily non-ART medications: ≤1.6 156 23.2% 247 25.4% 0.672 
Number of daily non-ART medications: >1.6 to 3.4 176 26.2% 246 25.3%  
Number of daily non-ART medications: >3.4 to 5.6 175 26.0% 234 24.1%  
Number of daily non-ART medications >5.6 166 24.7% 244 25.1%  
      
Comorbid Conditions/Comedications (N, %)           
   Few comorbidities/few daily  
   comedications 274 29.9% 380 52.3% <0.001 
   Many comorbidities/few daily  58 6.3% 113 15.5%   
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   comedications 
   Few comorbidities/many daily  
   comedications 185 20.2% 193 26.5%   
   Many comorbidities/many daily  
   comedications 156 17.0% 285 39.2%   
      
Comorbidities (N, %)      
Hypertension 363 53.9% 584 60.1% 0.012 
Dyslipidemia 355 52.7% 513 52.8% 0.973 
Diabetes 154 22.9% 294 30.3% 0.001 
Cataract 180 26.7% 228 23.5% 0.132 
Ischemic heart disease (Myocardial infarction, angina, atherosclerosis) 119 17.7% 225 23.2% 0.007 
Kidney disease 76 11.3% 194 20.0% <0.001 
Glaucoma 104 15.5% 145 14.9% 0.772 
Chronic pulmonary disease 82 12.2% 165 17.0% 0.007 
Cardiac dysrhythmia 82 12.2% 160 16.5% 0.016 
Anemia 68 10.1% 173 17.8% <0.001 
Benign prostate hyperplasia  80 11.9% 147 15.1% 0.060 
Depression 80 11.9% 133 13.7% 0.283 
Non-AIDS-defining cancer* 76 11.3% 131 13.5% 0.186 
Osteoarthritis 74 11.0% 105 10.8% 0.907 
Retinal disorders (including non-diabetic retinopathy, retinal or macular 
degeneration) 78 11.6% 100 10.3% 0.407 
Peptic ulcer disease/esophageal reflux 55 8.2% 104 10.7% 0.087 
Cerebrovascular disease 59 8.8% 93 9.6% 0.577 
Heart valve disorders (non-rheumatic) 48 7.1% 89 9.2% 0.142 
Peripheral vascular disease 40 5.9% 76 7.8% 0.143 
Congestive heart failure 31 4.6% 79 8.1% 0.005 
Substance abuse 36 5.3% 67 6.9% 0.202 
Anxiety 38 5.6% 60 6.2% 0.654 
Unspecified acquired hypothyroidism 43 6.4% 52 5.4% 0.377 
Hepatitis C 35 5.2% 51 5.3% 0.963 
Tobacco use disorder 27 4.0% 44 4.5% 0.610 
Osteoporosis 20 3.0% 37 3.8% 0.361 
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Dementia  17 2.5% 33 3.4% 0.311 
Liver disease 14 2.1% 29 3.0% 0.258 
Bipolar disorder 8 1.2% 11 1.1% 0.917 
Rheumatologic disease 7 1.0% 8 0.8% 0.650 
Hemiplegia/paraplegia 4 0.6% 9 0.9% 0.454 
Schizophrenia (including schizoaffective disorder) 2 0.3% 1 0.1% 0.364 
      
Comorbidity Class: 3-Class Solution      
Healthiest 345 51.3% 423 43.6% <0.001 
Hypertension/Dyslipidemia/Diabetes 292 43.4% 517 53.2%  
Hypertension/Dyslipidemia/Glaucoma/Cataracts  36 5.3% 31 3.2%  
      
Comorbidity Class: 4-Class Solution      
Healthiest 196 29.1% 240 24.7% <0.001 
Hypertension/Dyslipidemia  257 38.2% 418 43.0%  
Hypertension/Dyslipidemia/Cataracts  160 23.8% 170 17.5%  
Hypertension/Dyslipidemia/Diabetes/Ischemic Heart Disease/Renal 
Disease  60 8.9% 143 14.7%  
      
Pre-Period ART Use (N, %) 670 99.6% 874 90.0% <0.001 
PDC (Mean, SD) 83.3% 16.2% 60.2% 30.9% <0.001 
Median, interquartile range 89.6% 74.0%-95.1% 70.1% 41.1%-86.3%  
PDC≥80% (N, %) 452 67.2% 337 34.7% <0.001 
PDC≥95% (N, %) 170 25.3% 66 6.8% <0.001 
      
ART Medication in Index Regimen (Prescriptions Filled ±45 Days 
around Index Date)** (N, %)      
NNRTI 440 65.4% 448 46.1% <0.001 
PI 186 27.6% 367 37.8% <0.001 
Fusion Inhibitor/Entry Inhibitor 10 1.5% 29 3.0% 0.049 
Integrase Inhibitor 168 25.0% 275 28.3% 0.131 
NRTI 661 98.2% 842 86.7% <0.001 
Pharmacokinetic Enhancer (ritonavir or cobicistat) 174 25.9% 314 32.3% 0.005 
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Single Tablet Regimen on Index Date or During Follow-up (N, %) 365 54.2% 328 33.8% <0.001 
      
Mail Order ART Claim on Index Date or During Follow-up (N, %) 239 35.5% 378 38.9% 0.160 
Abbreviations: ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PDC, proportion 
of days covered; PI, protease inhibitor; PLWH, people living with HIV; SD, standard deviation. 
*excludes Kaposi's sarcoma, cervical cancer, non-Hodgkin's lymphoma 
**This reflects medications that patients filled around the index date (±45 days). Patients may have been on other ART classes as part of their ART regimen, but if 




Appendix 3 Figure 1A-B. Unadjusted (A) and adjusted (B) odds ratios for non-adherence, 








Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio; PDC, proportion of days covered. 
Models in 2B were adjusted for age, sex, region, urbanicity, types of ART classes filled ±45 days around the index 
date, presence of ≥1 claim for an ART single tablet regimen on the index date or during follow-up, presence of ≥1 
claim for ART filled via mail-order pharmacy on the index date or during follow-up, and pre-period ART adherence.
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Primary Exposure Variable      
  
      
      
  
      
Pre-Period Comorbid Conditions (based on quartiles)      
  
      
0-2 (reference), N=553 1.000     1.000         
3-4, N=479 
1.204 (0.904-







4       
5-6, N=339 
1.420 (1.035-







8       
≥7, N=273 
1.350 (0.957-







7       
               
Pre-Period Daily Comedications (based on quartiles)               
≤1.6 (reference), N=403   1.000   1.000         









0       









6       









9       
      
  
      
Pre-Period Comorbid Conditions*Daily Comedications (based 
on medians)       
  
      
Few comorbidities (≤4) and few daily comedications (≤3.4) 
(reference), N=654       
  
1.000       
Many comorbidities (>4) and few daily comedications (≤3.4), 
N=171       
  1.057 (0.719-
1.553) 0.780     
Few comorbidities (≤4) and many daily comedications (>3.4), 
N=378       
  0.783 (0.578-
1.062) 0.116     
Many comorbidities (>4) and many daily comedications (>3.4), 
N=441       
  1.205 (0.906-
1.602) 0.200     
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Pre-Period Comorbid Classes: 3 Class Solution      
  
      
"Healthiest" (reference), N=768     
  
  1.000     




1.661) 0.019   




1.409) 0.395   
      
  
      
Pre-Period Comorbid Classes: 4 Class Solution      
  
      
"Healthiest" (reference), N=436     
  
    1.000   
Hypertension/Dyslipidemia, N=675     
  
    
1.325 (0.999-
1.758) 0.051 
Hypertension/Dyslipidemia/Cataracts, N=330     
  




Disease/Renal Disease, N=203     
  
    
1.425 (0.963-
2.107) 0.076 
      
  
      
Covariates     
  
      
Age group      
  
      
65-69 (reference) 1.000   1.000   
1.000  
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Abbreviations: AOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse 
transcriptase inhibitor; PDC, proportion of days covered; PI, protease inhibitor. 
*Excluding 10 patients who had missing covariates. 
**Prescriptions filled ±45 days around index date 
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Appendix 3 Table 5. Adjusted odds ratios for non-adherence, defined as PDC<95% 
 AOR (95% CI) 
p-








e AOR (95% CI) 
p-
value AOR (95% CI) 
p-
value AOR (95% CI) 
p-
value 
      
  
      
Primary Exposure Variable      
  
      
      
  
      
Pre-Period Comorbid Conditions (based on quartiles)      
  
      
0-2 (reference), N=533 1.000     1.000         
3-4, N=479 
1.029 (0.785-







0       
5-6, N=339 
1.296 (0.953-







1       
≥7, N=273 
1.314 (0.932-







4       
               
Pre-Period Daily Comedications (based on quartiles)               
≤1.6 (reference), N=403   1.000   1.000         









0       









7       









4       
      
  
      
Pre-Period Comorbid Conditions*Daily Comedications (based 
on medians)       
  
1.000      
Few comorbidities (≤4) and few daily comedications (≤3.4) 
(reference), N=654      
  
        
Many comorbidities (>4) and few daily comedications (≤3.4), 
N=171      
  1.081 (0.734-
1.594) 0.693     
Few comorbidities (≤4) and many daily comedications (>3.4), 
N=378      
  0.638 (0.480-
0.848) 0.002     
Many comorbidities (>4) and many daily comedications (>3.4), 
N=441      
  1.093 (0.825-
1.448) 0.535     
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Pre-Period Comorbid Classes: 3 Class Solution      
  
      
"Healthiest" (reference), N=768     
  
  1.000     




1.644) 0.017   
Hypertension/Dyslipidemia/Glaucoma/Cataracts, 




1.196) 0.188   
      
  
      
Pre-Period Comorbid Classes: 4 Class Solution      
  
      
"Healthiest" (reference), N=436     
  
    1.000   
Hypertension/Dyslipidemia, N=675     
  
    
1.211 (0.925-
1.587) 0.164 
Hypertension/Dyslipidemia/Cataracts, N=330     
  




Disease/Renal Disease, N=203     
  
    
1.503 (1.010-
2.237) 0.045 
      
  
      
Covariates     
  
      
Age group      
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Abbreviations: AOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse 
transcriptase inhibitor; PDC, proportion of days covered; PI, protease inhibitor. 
*Excluding 10 patients who had missing covariates. 
**Prescriptions filled ±45 days around index date 
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Association between Latent Class and Adherence, Accounting for Uncertainty of Class 
Assignment 
For the comorbidity class exposure variables, unadjusted logistic regression models were fit 
using the PROC LCA distal macro developed at the Pennsylvania State University.1 This macro 
accounts for the uncertainty in assigned class from the latent class model, which is probabilistic 
rather than deterministic. However, it cannot incorporate covariate adjustment; therefore, results 
are unadjusted.  
When I used the LCA distal macro, individuals in the hypertension/dyslipidemia/diabetes class 
were more likely to be non-adherent than healthiest individuals in the 3-class solution 
(OR=1.761, 95% CI 1.305-2.377, p<0.001). In the 4-class solution, PLWH in the 
hypertension/dyslipidemia class (OR=1.825, 95% CI 1.161-2.871, p=0.009) and PLWH in the 
hypertension/dyslipidemia/diabetes/ischemic heart disease/renal disease class (OR=2.289, 
95% CI 1.410-3.717, p<0.001) were more likely to be non-adherent than PLWH in the healthiest 
class.  
With the 95% cut-off, the hypertension/dyslipidemia/diabetes class were significantly more likely 
to be more non-adherent than healthiest individuals in the 3-class solution (OR=1.741, 95% CI 
1.286-2.358, p<0.001). In the 4-class solution, PLWH in the 
hypertension/dyslipidemia/diabetes/ischemic heart disease/renal disease class were 
significantly more likely to be non-adherent than PLWH in the healthiest class (OR=2.777, 95% 
CI 1.547-4.984, p<0.001).  
Mediation Analysis 
To test if out-of-pocket costs are a mediator of the association between comorbid disease/co-
medication and ART adherence, I used a mediation macro developed by Valeri et al.2 Based on 
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Pearl’s methodology, I evaluated the total effect (i.e., the effect on the outcome of moving from 
unexposed to exposed when the mediator changes based on its association with the exposure), 
the natural indirect effect (i.e., the effect on the outcome when the exposure is held constant but 
the mediator changes to the value it would have attained if each individual was unexposed) and 
the controlled direct effect (i.e., the effect of moving from unexposed to exposed given a 
specified level of the mediator).3 I classified PLWH as having a number of comorbidities less 
than or equal to the median (≤4.0 comorbidities) vs. more than the median, having a number of 
daily comedications less than or equal to the median (≤3.4 comedications) vs. more than the 
median, and if the total out-of-pocket costs (patient paid amounts including deductible, 
copayment, and coinsurance on medical and pharmacy claims) were less than or equal to the 
median (≤$1,375.48). Both unadjusted and adjusted mediation models were fit. Adjusted 
models controlled for covariates described in Chapter 4. To assess the control direct effect, the 
mediator, total out-of-pocket costs, was set to less than the median. 
The results are presented in Appendix 3 Table 6. In unadjusted models, the controlled direct 
effect and the total effect were statistically significant for comorbid conditions, which were 
associated with greater odds of non-adherence. These effects were not significant in the 
unadjusted models of comedications. The indirect effect of total out-of-pocket costs was not 
significant in either unadjusted model. In the adjusted model assessing the impact of comorbid 
disease burden on ART adherence, the controlled direct effect was statistically significant, and 
the total effect nearly reached significance. The indirect effect was again insignificant. In the 
adjusted models, the controlled direct effect, indirect effect, and total effect of comedication 
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Appendix 3 Table 6. Analysis of comorbid disease and comedication burden and ART 
adherence (PDC<80% vs. PDC≥80), mediated by total out-of-pocket costs 
 Unadjusted Adjusted 
 OR 95% CI p-value OR 95% CI p-value 
Exposure: Comorbidities       
   Controlled Direct Effect 1.536 1.245-1.896 <0.001 1.279 1.003-1.632 0.047 
   Natural Indirect Effect 0.964 0.919-1.012 0.140 0.988 0.929-1.050 0.696 
   Total Effect 1.481 1.207-1.818 <0.001 1.264 0.997-1.601 0.053 
       
Exposure: 
Comedications 
      
   Controlled Direct Effect 0.955 0.776-1.174 0.659 0.985 0.774-1.253 0.901 
   Natural Indirect Effect 0.987 0.932-1.045 0.644 1.004 0.933-1.080 0.921 
   Total Effect 0.942 0.772-1.149 0.554 0.988 0.784-1.246 0.922 
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio; PDC, proportion of days covered.
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In Aim 1 and 2, compared to HIV-negative individuals in unadjusted analyses, a higher 
proportion of PLWH lived in segregated neighborhoods and neighborhoods with concentrated 
poverty. A smaller proportion of PLWH compared to HIV-negative individuals lived in 
neighborhoods with lower education levels, although this difference was no longer evident when 
comparing PLWH with the matched HIV-negative cohort in my second analysis. I included zip 
code level characteristics as individual-level variables in sex-specific models for my first analysis 
of number of non-HIV conditions and number of daily non-ART medications. The effect 
estimates were small in magnitude, though significant because of the large sample sizes, when 
evaluating the impact on the number of non-HIV conditions (range 1.011 to 1.052) and the 
number of non-ART medications (range 0.952 to 1.071). The effect estimates were larger for the 
association between living in a segregated neighborhood and odds of having no non-ART 
medication (men OR=1.44, 95% CI 1.40-1.49; women OR=1.31, 95% CI 1.27-1.35).  
In the LCA, no neighborhood characteristics were significantly associated with latent class 
assignment in the model of PLWH. In the model of matched HIV-negative individuals, those 
living in neighborhoods with lower educational attainment were more likely to belong to the 
hypertension/dyslipidemia class or the sickest class compared to the healthiest class than 
people living in neighborhoods with higher educational attainment (ORs=1.31, 95% CI 1.18-1.44 
and 1.54, 95% CI 1.33-1.78, respectively). In the model of all HIV-negative individuals, living in 
a segregated neighborhood or a neighborhood with lower education levels was associated with 
greater odds of being in the hypertension/dyslipidemia or sickest class compared to the 
healthiest class (segregation: ORs=1.16, 95% CI 1.14-1.19 and 1.19, 95% CI 1.16-1.22; 
education: ORs=1.21, 95% CI 1.19-1.22 and 1.35, 95% CI 1.34-1.37). Living in a neighborhood 
with concentrated poverty was associated with lower likelihood of being in the 
hypertension/dyslipidemia class compared to the healthiest class (OR=0.97, 95% CI 0.95-0.98), 
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but greater likelihood of being in the sickest class vs. the healthiest class (OR=1.05, 95% CI 
1.04-1.07), although the magnitudes of the effects were small. 
In the third analysis, a greater proportion of non-adherent patients lived in a segregated 
neighborhood (17.7% vs. 10.5%, p<0.001) or in a neighborhood with low educational attainment 
(50.0% vs. 41.9%, p=0.001) compared to adherent patients using an 80% cut-off to define 
adherent vs. non-adherent. When a 95% cut-off was used, a greater proportion of non-adherent 
patients lived in a segregated neighborhood (16.3% vs. 8.9%, p<0.001) or in a neighborhood 
with low educational attainment (48.1% vs. 40.6%, p=0.003) compared to adherent patients. 
There were no significant differences in the proportions of PLWH living in a neighborhood with 
concentrated poverty or living in counties where the provider concentrations were below the 
median between the two cohorts using either definition of adherent.  
In multivariable models with non-adherent defined as PDC<80% and PDC<95%, living in a 
neighborhood with segregation was consistently significantly associated with greater odds of 
non-adherence across models with different comorbid/comedication exposure variables. In the 
models using the 80% cutoff, the odds ratios ranged from 1.592 (95% CI 1.094-2.316) to 1.616 
(95% CI 1.110-2.353) and in the models using the 95% cutoff, the odds ratios ranged from 
1.719 (95% CI 1.162-2.543) to 1.777 (95% CI 1.200-2.631). No other neighborhood 
characteristics were significantly associated with non-adherence in the 80% or 95% models. 
 
 
